Completed drafting packet · October 18, 2026
Ibuprofen
AI-assisted draft, not yet reviewed
Explore the expanded explanation and evidence prepared for this medicine. This review edition is separate from the current visual guide.
Open the current guide and visual story →
Choose your perspective
Each view has its own explanation. Some older-page packets contain targeted FAQ repairs only; those are identified below.
Patient
Ibuprofen slows two enzymes, COX-1 and COX-2. In sore tissue, this lowers signals that make pain nerves more sensitive. Pain and swelling can ease. A standard tablet reaches its peak blood level in 1–2 hours. The same pathway helps protect the gut and keep blood flowing through the kidneys. The prescription label warns of serious gut bleeding, heart attack and stroke. It rules out use around heart bypass surgery and after certain aspirin or NSAID allergy reactions. A pharmacist can check the exact product and your other medicines.
Limits: This explanation cannot choose a dose or replace the full product warnings.
Questions for this perspective
2 drafted questions in this packet. Targeted additions or replacements for the current guide.
Can I take ibuprofen with low-dose aspirin?
Established. Ibuprofen can block part of aspirin’s effect on blood platelets. In one label study, plain aspirin given two hours before a single daily dose of ibuprofen kept that effect. Coated aspirin and repeated doses need their own review. This is not a safe schedule for everyone. Ask a pharmacist to check the exact drugs, their purpose and timing. Do not change prescribed aspirin based on this story.
Routing: interactions / role variant.
How is checking for harm different from checking relief?
Established. Less pain shows a symptom has changed. It does not show that the medicine is free of harm. A clinician may check blood pressure, kidney tests or blood counts when use continues or risks are higher. At home, note new swelling, less urine, stomach symptoms or rash. The label treats chest pain, trouble breathing, black stools and blood in vomit as urgent warning signs. Share both the benefit and any new problem with the care team.
Routing: monitoring / role variant.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
Why might it help? — Ibuprofen can ease pain and fever. This story follows a standard tablet from the gut to the blood, then to the signals it changes in tissues. Less pain can make rest or movement easier. The product label gives the directions for use. ["RX", "OTC"]
-
Why this pain medicine? — A swallowed tablet passes into the stomach and gut. It must break up and release the drug before the drug can reach the blood. The whole tablet does not travel to a sore muscle. ["RX"]
-
What happens after swallowing? — The drug dissolves in fluid in the gut. Ibuprofen has low water solubility: below one milligram per milliliter in the selected label. The way a product is made affects how it releases the drug. ["RX", "FAST"]
-
How does it reach the body? — Dissolved ibuprofen enters the blood from the gut. Blood carries it to tissues throughout the body. This broad reach helps explain both relief and unwanted effects in places such as the stomach and kidneys. ["RX"]
-
How does it lower pain signals? — Ibuprofen slows COX-one and COX-two, enzymes that help tissues make signals called prostaglandins. In sore tissue, some of these signals make pain nerves more sensitive. Less of the signal can ease pain and swelling. The same enzymes also help protect the gut and support blood flow in the kidneys. ["MECH", "PHYS", "RX"]
-
When might you notice relief? — A clinical handbook estimates that pain relief can begin in thirty to sixty minutes after an oral dose. A standard tablet reaches its peak blood level in one to two hours. These are different events. The exact product, symptom and person affect the timing. ["PAT", "RX", "FAST"]
-
Why does the effect wear off? — The liver changes much of the drug, and urine carries out mainly those changed forms. The serum half-life is about two hours. This is a measure of how blood levels fall. It is not a rule for when another dose is allowed. ["RX", "PK"]
-
How can you use it sensibly? — Check every pain and cold product for its active ingredients. Some contain ibuprofen, so two brands can give the same drug. Other NSAIDs, such as naproxen, can add risk. A pharmacist can check aspirin, blood thinners and the rest of the medicine list. ["RX", "OTC"]
-
Does body size change the dose? — The adult tablet label does not increase its maximum for a larger adult. A child needs the directions for the child’s own product, which can depend on weight and strength. A liquid also needs the right measuring device. The pharmacist can check these details with the person giving it. ["OTC", "PAT"]
-
When could another dose be taken? — Here is one US label example, not a personal dose plan. The Advil two-hundred-milligram tablet label allows one tablet every four to six hours for ages twelve and over; two may be used if one does not help. It limits use to six tablets in twenty-four hours unless a doctor directs otherwise. Under twelve, it says to ask a doctor. ["OTC"]
-
When should symptoms be checked? — The OTC label says to stop use and ask a doctor if pain gets worse or lasts more than ten days, or fever gets worse or lasts more than three days. A new or severe symptom needs prompt advice. Earlier relief does not prove that the cause has gone away. ["OTC"]
-
Possible side effects to watch for — The prescription label warns of heart attack, stroke and serious gut bleeding, ulcers or holes in the gut. These can be fatal. It rules out use around heart bypass surgery, after ibuprofen allergy or certain aspirin or NSAID reactions, and after a serious NSAID skin reaction. Kidney, heart, gut or liver problems need a professional check. ["RX"]
-
Important warning signs — The label calls for urgent help for signs such as chest pain, trouble breathing, one-sided weakness, blood in vomit, black stools or face and throat swelling. From twenty weeks of pregnancy, the OTC label warns against use unless a doctor advises it. Keep the exact package and medicine list ready when asking for help. ["RX", "OTC", "FDA"]
Evidence: Established; physiology is textbook-level synthesis with experimental sources, not a newly validated animation.
Caregiver
Ibuprofen slows COX-1 and COX-2 in tissues, reducing signals that make pain nerves more sensitive. The person you help may move or rest with less pain. A standard tablet peaks in the blood in 1–2 hours. Keep a record of the product, strength and time given. Check cold remedies for the same drug. Adult tablets and child liquids have different directions. Ask a pharmacist to check aspirin, blood thinners and other pain drugs. Watch for black stools, blood in vomit or trouble breathing; these signs need urgent help.
Limits: Symptom relief does not establish recovery from the underlying illness.
Questions for this perspective
7 drafted questions in this packet. Targeted additions or replacements for the current guide.
What improvement should I watch for?
Established. Ibuprofen can ease pain and fever. For the person you help, choose a simple way to note that change: easier walking, better rest or less pain with a task. Record the symptom before and after a dose, along with the time and exact product. Relief is useful even when the cause still needs care. Bring the record to the pharmacist or clinician if symptoms persist or change.
Routing: use / role variant.
What if the dose record is unclear?
Established. A shared record helps prevent two helpers from giving the same dose. Write the product, strength, amount and time as soon as it is given. If no one knows whether a dose was taken, ask a pharmacist for advice based on the actual product and plan. Do not use pain alone to guess what was given. As-needed treatment and a scheduled prescription have different goals; the care plan should make that clear.
Routing: missed / role variant.
What information helps after a possible extra dose?
Established. After a possible extra dose, get urgent advice from a poison center or medical team. Keep the package and dose record ready. State the strength, amount and time, plus other drugs taken. Do not wait for symptoms to judge whether the amount was safe. A cold remedy may also contain the drug. The OTC label says to get medical help or contact a poison control center right away after an overdose.
Sources: OTC
Routing: overdose / role variant.
How can I tell whether activity is improving?
Established. Notice a task that matters to the person, such as walking to the bathroom or sleeping without pain. Record whether it becomes easier, as well as the pain score. Feeling less pain is not proof that an injury has healed. New dizziness or trouble staying steady can make a task less safe. Share these changes with the care team, especially if the person cannot describe symptoms clearly.
Routing: activities / role variant.
What should carers check on the package?
Established. Keep the medicine in its original labeled container so every helper can check the ingredient, strength and directions. Store it as that package directs and out of reach of children. Do not use an unmarked pill box as the only record of what a tablet contains. Bring the package when a pharmacist checks the medicine list. Products with similar names may have different ingredients or strengths.
Routing: storage / role variant.
Why does poor fluid intake matter?
Established. Fluid loss can put stress on the kidneys. This can happen with vomiting, loose stools or poor intake. Ibuprofen lowers signals that help keep blood flowing through the kidneys. Tell the care team about less urine, swelling or new weakness before repeated use. Keep a record of symptoms and doses. If a dose was vomited, no one can tell from that alone how much stayed in the body. Ask for advice instead of giving a guessed amount.
Routing: illness / role variant.
How is a liquid different from an adult tablet?
Established. A liquid has a concentration as well as a volume. Both matter when checking a dose. Use the measuring device supplied with the product or one the pharmacist recommends, rather than a kitchen spoon. The adult tablet label does not set a child’s dose. Ask the pharmacist to show the helper how to read the marks and then use teach-back to check that the product and amount are understood.
Routing: devices / role variant.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
What are you helping with? — Agree on what the person hopes to do with less pain, such as walk or rest. Note the symptom before and after a dose. A useful change in comfort or function helps the care team judge benefit. ["RX"]
-
Which product is intended? — Keep one record of the product, strength, amount and time given. Check cold remedies for ibuprofen. Adult tablets do not set a child’s dose. For a liquid, the concentration and measuring device both matter. Share the record so helpers do not repeat a dose by mistake. ["OTC", "PAT"]
-
How does it help? — Ibuprofen slows COX-one and COX-two in tissues. These enzymes help make signals that make pain nerves more sensitive. Less signal can mean less pain. The pathway also helps protect the gut and keep blood flowing through the kidneys, so relief and harm can occur together. ["MECH", "RX"]
-
What response should you expect? — Pain relief may start in thirty to sixty minutes, according to a clinical handbook. Note whether the person can do the agreed task more easily. The next dose still follows the actual label or care plan. A fall in pain alone does not show that the cause has resolved. ["PAT", "OTC"]
-
When is help needed? — Blood in vomit, black stools or trouble breathing need urgent help. Report poor fluid intake, less urine, swelling or new rash to the care team. Bring the package and record when asking about aspirin, blood thinners or other pain drugs. ["RX", "OTC"]
Evidence: Established; physiology is textbook-level synthesis with experimental sources, not a newly validated animation.
Pharmacist
Ibuprofen reversibly inhibits COX-1 and COX-2, reducing prostanoid synthesis in inflamed tissue and platelet thromboxane generation. Acute postoperative evidence gives a pooled NNT of 2.5 for at least 50% pain relief over 4–6 hours with 400 mg. Reconcile aspirin formulation and regimen before interpreting interference studies. Boxed warnings cover serious cardiovascular thrombosis and gastrointestinal bleeding, ulceration and perforation. Contraindications include hypersensitivity, aspirin/NSAID-triggered allergic reactions and perioperative CABG use; prior serious NSAID skin reactions also preclude use under Warnings. Connect renal perfusion risk, interacting medicines and product-specific directions in counseling.
Limits: Immediate-release aspirin findings cannot be generalized to every formulation or schedule.
Questions for this perspective
6 drafted questions in this packet. Targeted additions or replacements for the current guide.
How should food counseling distinguish comfort from protection?
Established. Food can slow ibuprofen absorption without substantially reducing its extent. The selected OTC label permits food or milk if stomach upset occurs. In Moore’s review, standard ibuprofen acid had mean Tmax of 1.34 hours fasted versus 1.96 hours fed across six comparisons. Food tolerance and ulcer prevention are separate outcomes: a comfortable stomach does not exclude bleeding. Explain the actual product directions and assess gastrointestinal risk rather than presenting food as gastroprotection or faster absorption as a universal priority.
Routing: administration / role variant.
What exactly do the aspirin studies support?
Established. The label reports 99.2% thromboxane inhibition when immediate-release aspirin 81 mg preceded once-daily ibuprofen 400 mg by two hours; ibuprofen two hours before aspirin yielded 53%. Enteric-coated aspirin with ibuprofen three times daily yielded 67%. A different immediate-release aspirin/TID regimen averaged 98.3%, with individual variability. These are regimen-specific pharmacodynamic experiments, not clinical-event guarantees. Reconcile aspirin formulation, indication and repeated ibuprofen exposure, and discuss an alternative analgesic when appropriate rather than supplying a universal spacing rule.
Routing: interactions / role variant.
What does a faster formulation actually establish?
Established. Moore’s review found median Tmax of 29–35 minutes for arginine, lysine and sodium salts, compared with 90 minutes for standard ibuprofen. Clinical studies also supported faster onset for some formulations, particularly in dental pain. Verify the exact marketed product and study rather than assuming every soft capsule or salt behaves identically. The selected Advil label is for 200 mg acid tablets/caplets. Faster absorption does not remove gastrointestinal, renal or cardiovascular warnings or authorize a shorter dosing interval.
Routing: formulation / role variant.
Which label applies to a purchased product?
Established. US OTC and prescription ibuprofen have distinct directions, strengths and intended supervision. The selected Advil Drug Facts cover 200 mg tablets/caplets, while the selected manufacturer prescription label covers 400, 600 and 800 mg tablets. Verify the product identifier, active ingredients and directions before counseling, including combination cold remedies. Availability without a prescription does not resolve contraindications, pregnancy restrictions or interactions. For cost comparisons, use an exact pack and retailer date instead of comparing an OTC bottle with an unrelated prescription strength.
Routing: access / role variant.
How should renal and older-adult risk change the review?
Established. The prescription label discourages use in advanced renal disease and identifies dehydration, heart failure, older age and interacting therapies as renal-risk contexts. AGS Beers 2023 recommends avoiding oral NSAIDs at creatinine clearance below 30 mL/min and generally avoiding chronic use in older adults unless alternatives fail and gastroprotection is possible. A proton-pump inhibitor reduces but does not eliminate gastrointestinal risk. Assess indication, duration, kidney function and the full medicine list; age alone is not a substitute for that review.
Routing: specialPopulations / role variant.
Which exclusions must be distinguished from precautions?
Established. The prescription label contraindicates ibuprofen hypersensitivity, aspirin/NSAID-associated asthma, urticaria or allergic-type reactions, and perioperative use in coronary artery bypass graft surgery. Its serious-skin-reaction warning also excludes patients with previous serious NSAID skin reactions. Boxed warnings concern potentially fatal cardiovascular thrombosis and gastrointestinal bleeding, ulceration or perforation. Prior bleeding, renal disease, recent myocardial infarction, severe heart failure and pregnancy require additional assessment under the warnings. Preserve these distinctions when documenting the screen; a short formal contraindication list does not define all unsuitable use.
Sources: RX
Routing: contraindications / role variant.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
What is the treatment goal? — Establish indication, formulation, strength and intended duration before comparing evidence. Separate acute analgesia from scheduled arthritis treatment. The label’s lack of additional acute analgesia above four hundred milligrams does not define an arthritis ceiling or replace OTC directions. ["RX"]
-
How does the mechanism inform counseling? — Reversible COX-one and COX-two inhibition reduces prostanoid production in inflamed tissue and platelet thromboxane generation. Link analgesic benefit with loss of gastric and renal protective signaling. The boxed warning covers serious cardiovascular thrombosis and gastrointestinal bleeding, ulceration and perforation. ["RX", "MECH"]
-
Which formulation and timing apply? — Standard tablet Tmax is one to two hours. Faster salts had median Tmax of twenty-nine to thirty-five minutes in Moore’s review. Food can slow absorption without materially reducing its extent. Match onset claims to the actual formulation and clinical endpoint. ["RX", "FAST", "FOOD"]
-
What must be reconciled? — Reconcile aspirin formulation and frequency, anticoagulants, other NSAIDs, diuretics and renin–angiotensin blockers. Once-daily ibuprofen two hours after immediate-release aspirin preserved platelet inhibition in one label study. Enteric-coated aspirin and repeated regimens require separate interpretation. Check hypersensitivity, aspirin or NSAID allergy, CABG context and previous serious NSAID skin reactions. ["RX", "ASPIRIN"]
-
What should the person leave knowing? — Use teach-back for ingredient, directions, intended duration and warning signs. Review pregnancy restrictions, kidney and cardiovascular risk, and the need for reassessment. For an available CYP2C9 result, use the phenotype-specific CPIC recommendation with clinical context. ["OTC", "RX", "CPIC"]
Evidence: Established; physiology is textbook-level synthesis with experimental sources, not a newly validated animation.
Clinician
Ibuprofen inhibits COX-1 and COX-2 reversibly, reducing prostanoid production in inflamed tissue and improving pain and function. High-dose trial evidence separates major coronary events, RR 2.22, from the nonsignificant major vascular estimate, RR 1.44. Assess baseline cardiovascular, gastrointestinal and renal risk before interpreting those relative effects. Boxed warnings include potentially fatal cardiovascular thrombosis and gastrointestinal bleeding, ulceration or perforation. Hypersensitivity, aspirin/NSAID allergic reactions and perioperative CABG use are contraindications; the label also excludes previous serious NSAID skin reactions. For osteoarthritis, NICE places topical treatment before oral NSAIDs when appropriate and recommends gastroprotection with oral treatment.
Limits: Relative risks from high-dose trials do not quantify an individual short-course risk.
Questions for this perspective
6 drafted questions in this packet. Targeted additions or replacements for the current guide.
What supports a duration decision?
Established. Duration should follow the indication, response and risk assessment rather than the serum half-life alone. The label recommends the lowest effective dose for the shortest appropriate duration; acute analgesia and ongoing arthritis treatment are different settings. OTC directions specify reassessment when pain worsens or lasts more than ten days or fever worsens or lasts more than three days. For continuing treatment, define a functional target, review date and toxicity monitoring. Persistent symptoms may require diagnosis-directed treatment rather than additional symptomatic exposure.
Routing: duration / role variant.
Does loss of relief imply pharmacologic tolerance?
Established. The label establishes symptomatic benefit and exposure-related risks, but does not demonstrate a single molecular tolerance mechanism explaining every loss of relief. Reassess the diagnosis, pain phenotype, adherence, formulation and duration before interpreting a changing response. Acute pain studies found no added analgesia above 400 mg, while arthritis regimens have a different evidence base. A cessation or replacement plan belongs to clinical assessment, particularly when another analgesic or aspirin is involved; the mechanism animation cannot set an individual switching schedule.
Sources: RX
Routing: stopping / role variant.
Where does ibuprofen sit in osteoarthritis care?
Established. NICE NG226 recommends topical NSAIDs for knee osteoarthritis and considering them for other joints. If topical treatment is ineffective or unsuitable, it recommends considering an oral NSAID with gastrointestinal, renal, liver, cardiovascular, pregnancy and concomitant-treatment risks assessed. It also recommends gastroprotection during oral NSAID treatment. These recommendations accompany nonpharmacological management and the lowest effective dose for the shortest time. They are UK osteoarthritis guidance, not a hierarchy for every pain syndrome or evidence that oral ibuprofen is suitable for every patient.
Routing: alternatives / role variant.
What does PRECISION establish about comparative safety?
Established. PRECISION randomized 24,081 arthritis patients with increased cardiovascular risk. Primary cardiovascular events occurred in 2.3% with celecoxib, 2.5% with naproxen and 2.7% with ibuprofen; celecoxib versus ibuprofen HR was 0.85, with 95% CI 0.70–1.04. The trial supported celecoxib noninferiority at the studied doses, not cardiovascular superiority. Mean ibuprofen dose was 2,045 mg/day. High treatment discontinuation and follow-up loss constrain interpretation. Do not extrapolate this comparison directly to occasional OTC use, higher celecoxib doses or all patient risk profiles.
Sources: PRECISION
Routing: comparison / role variant.
How does CYP2C9 information enter prescribing?
Established. CPIC 2020 distinguishes CYP2C9 intermediate metabolizers with activity scores of 1.5 and 1: the former use the recommended starting dose, while the latter start at the lowest recommended dose with cautious titration and monitoring. For poor metabolizers, CPIC describes a substantially reduced starting range or an alternative, with delayed titration because elimination is prolonged. This guidance interprets an available genotype; it is not a universal testing requirement. Combine genotype with kidney function, age, comedications and the actual treatment indication.
Routing: patientVariability / role variant.
Who was actually studied in PAIN?
Established. PAIN studied adults aged 18–75 consulting French general practitioners for short-term pain. Of 8,677 randomized participants, 8,633 were evaluable for the principal analysis. Treatment lasted one to seven days, with ibuprofen up to 1,200 mg/day versus aspirin or paracetamol up to 3 g/day. The significant-adverse-event endpoint included moderate/severe events and discontinuation-related criteria. This Boots-funded tolerability comparison does not establish safety in excluded high-risk patients, pregnancy or long-term treatment, nor the absence of rare bleeding or cardiovascular events.
Sources: PAIN
Routing: evidence / clinician-06.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
Why consider ibuprofen? — Define pain and functional outcomes before selecting an NSAID. NICE osteoarthritis guidance places topical therapy before oral treatment when appropriate, with organ-risk assessment and gastroprotection for oral use. This guidance is indication-specific. ["NICE"]
-
What is the pharmacologic rationale? — Reversible COX-one and COX-two inhibition lowers prostanoid synthesis in inflamed tissue, supporting analgesia. The same pathway contributes to renal perfusion and gastric protection. Benefit and harm therefore require assessment together, especially during volume depletion or concomitant antithrombotic treatment. ["MECH", "RX"]
-
What does exposure tell us? — Serum half-life is one point eight to two hours for the selected tablet. Rapid elimination does not prevent on-treatment gastrointestinal, renal or cardiovascular injury. Use formulation, dose, duration and baseline risk to interpret exposure rather than inferring safety from half-life. ["RX"]
-
What should guide continued use? — Track function as well as pain intensity. For continuing therapy, reassess diagnosis and disease-directed options, blood pressure, edema, renal function and appropriate blood or chemistry tests. The label recommends the lowest effective dose for the shortest suitable duration. ["RX"]
-
What changes the benefit–risk balance? — The boxed warning covers potentially fatal cardiovascular thrombosis and gastrointestinal bleeding, ulceration or perforation. Exclusions include hypersensitivity, aspirin or NSAID allergy, perioperative CABG and previous serious NSAID skin reactions. CNT’s high-dose coronary risk and PRECISION’s active-comparator noninferiority result answer different questions. Pregnancy restrictions require separate attention. ["RX", "CNT", "PRECISION", "FDA"]
Evidence: Established; physiology is textbook-level synthesis with experimental sources, not a newly validated animation.
Nurse
Ibuprofen reversibly inhibits COX-1 and COX-2 in tissues, reducing prostaglandin production and measurable pain or fever. Record the baseline symptom and a functional goal, then document response after administration. Standard tablets peak in serum in 1–2 hours. Reconcile doses already taken and assess hydration, urine output, blood pressure and bleeding concerns within the care plan. The boxed warning covers serious cardiovascular events and gastrointestinal bleeding, ulceration and perforation. Check hypersensitivity, aspirin/NSAID allergy, perioperative CABG and previous serious NSAID skin reactions before administration. Escalate concerning symptoms promptly and use teach-back to separate relief timing from the permitted dosing interval.
Limits: The animation does not replace local administration and escalation protocols.
Questions for this perspective
2 drafted questions in this packet. Targeted additions or replacements for the current guide.
How should symptom benefit be documented?
Established. Record both symptom intensity and a concrete function before administration, then reassess according to the order and local protocol. Ibuprofen can improve pain, fever and movement without resolving the underlying disorder. Standard oral tablets reach peak serum levels in 1–2 hours, which is not a mandatory nursing reassessment interval. Document timing, route, formulation and any adverse symptoms so subsequent staff can interpret the response. A falling pain score and a new bleeding or renal concern must be communicated as separate findings.
Sources: RX
Routing: benefit / role variant.
Which findings need escalation?
Established. The boxed warning covers serious cardiovascular thrombosis and gastrointestinal bleeding, ulceration and perforation, sometimes without warning symptoms. Escalate chest pain, focal weakness, breathing difficulty, hematemesis or black stools through the urgent-care pathway. Facial or throat swelling and a severe skin reaction also require prompt assessment. Record recent doses, concomitant drugs and symptom onset. The same prostanoid pathway that supports analgesia also supports renal perfusion, so new oliguria, fluid retention or deteriorating renal status warrants review within the clinical protocol.
Routing: urgent / role variant.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
What is the care goal? — Verify indication, route, strength and the last dose, including medicines brought from home. Record a baseline symptom and functional goal. Reconcile duplicates and check allergy, bleeding, hydration and renal concerns against the order and local protocol. ["RX", "OTC"]
-
How can you explain its action? — Ibuprofen inhibits COX-one and COX-two in tissues. Reduced prostaglandin production can lower pain and fever, while reduced protective signaling can affect the stomach and kidneys. Explain both sides of that pathway in the patient’s own terms. ["RX", "MECH"]
-
What response should you observe? — Standard oral tablets peak in serum after one to two hours. Reassess pain and function according to the clinical order and local protocol; serum peak is not a universal reassessment interval. Document benefit and adverse symptoms separately. ["RX"]
-
What should be escalated? — Escalate chest pain, focal weakness, breathing difficulty, hematemesis, black stools or severe skin symptoms promptly. Boxed warnings include cardiovascular thrombosis and serious gastrointestinal injury. Confirm exclusions for hypersensitivity, aspirin or NSAID allergy, perioperative CABG and prior serious NSAID skin reactions. ["RX"]
-
What should the person understand? — Ask the person to explain the ingredient, directions and warning signs back to you. Distinguish expected relief timing from the next permitted dose. Record new swelling, reduced urine output or poor intake, and communicate concerns using the care setting’s escalation process. ["RX", "OTC"]
Evidence: Established; physiology is textbook-level synthesis with experimental sources, not a newly validated animation.
Student
Ibuprofen reversibly inhibits COX-1 and COX-2, reducing conversion of arachidonic acid toward prostanoid precursors. In inflamed tissue, less prostaglandin signaling reduces pain sensitization; in thermoregulatory pathways, reduced signaling lowers fever. Protective stomach and renal pathways explain toxicity from the same target family. A serum half-life of 1.8–2 hours describes elimination, not a dosing instruction. Contrast reversible ibuprofen binding with aspirin acetylation of platelet COX-1. Follow the chain from enzyme to tissue mediator to measured clinical outcome, while distinguishing biochemical assays, structural models and patient trials.
Limits: Pathway diagrams simplify tissue-specific signaling and feedback.
Questions for this perspective
3 drafted questions in this packet. Targeted additions or replacements for the current guide.
Why is this an NSAID rather than a steroid?
Established. Ibuprofen is a propionic-acid nonsteroidal anti-inflammatory drug. It inhibits COX-1 and COX-2 reversibly, reducing prostanoid formation in inflammatory tissues and thereby decreasing pain sensitization and fever signaling. Steroids act through a different receptor-mediated regulatory system; the shared term anti-inflammatory does not imply interchangeable mechanisms or risks. Ibuprofen is also neither an antibiotic nor an opioid. Learn the target–tissue–effect chain alongside the class name, and distinguish symptomatic relief from treatment of an infection or disease process.
Routing: class / role variant.
Are COX-1 and COX-2 simply good and bad enzymes?
Established. Both isoforms participate in physiology as well as disease. Platelet COX-1 supports thromboxane formation, while prostanoids support gastric mucosal protection and renal blood flow. COX-2 contributes to inflammatory signaling but also has constitutive functions in tissues such as the kidney. Ibuprofen inhibition can therefore reduce pain in inflamed tissue while impairing protective signaling elsewhere. A good-enzyme/bad-enzyme cartoon would misrepresent this balance. Tissue context, mediator production and clinical exposure are needed to interpret a COX selectivity claim.
Routing: target / role variant.
Why does relief not prove that an injury healed?
Established. Ibuprofen inhibits COX-1 and COX-2 and reduces prostaglandin signaling around pain-sensitive tissue. This can reduce the amplification of pain without repairing damaged tissue or removing an infectious cause. Symptom intensity is therefore one outcome, not a direct assay of healing. The label directs reassessment of persistent or worsening symptoms. A mechanism diagram should connect analgesia to signaling and reserve claims about disease resolution for studies that actually measure that outcome in the relevant condition.
Routing: uncertainty / role variant.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
Why learn this drug? — Follow a causal chain: enzyme inhibition, changed tissue mediators and a clinical outcome. Ibuprofen inhibits COX-one and COX-two reversibly. Less prostanoid signaling in inflamed tissue reduces pain sensitization; reduced protective signaling helps explain gastrointestinal and renal harm. ["MECH", "RX"]
-
How does an oral dose reach tissues? — A tablet releases drug that dissolves and enters blood through the gut. Plasma protein binding exceeds ninety-nine percent in the cited reference. Distinguish total from unbound exposure, and distinguish a plasma measurement from concentration at a tissue target. ["RX", "PK"]
-
How does the target connect to relief? — Cytosolic phospholipase A-two releases arachidonic acid from membranes. COX enzymes generate prostanoid precursors; tissue synthases then produce different mediators. PGE-two acts through EP receptors in pain and fever pathways. Receptor-knockout experiments support the hypothalamic EP-three fever mechanism, while patient trials establish the drug’s clinical antipyretic effect. ["PHYS", "MECH", "RX"]
-
What changes for the person? — Both COX isoforms have physiological roles. Platelet thromboxane, gastric protection and renal perfusion show why COX-one is not simply bad or COX-two simply good. A standard tablet’s one-to-two-hour serum peak is a disposition result, not a measurement of healing. ["PHYS", "RX"]
-
Why can the same drug cause harm? — Aspirin acetylates platelet COX irreversibly, whereas ibuprofen binding is reversible. Ibuprofen can obstruct aspirin’s access in regimen-dependent experiments. The distinction explains an interaction hypothesis, but a universal spacing instruction requires more than the word reversible. ["ASPIRIN", "RX", "MECH"]
Evidence: Established; physiology is textbook-level synthesis with experimental sources, not a newly validated animation.
Scientist
Ibuprofen reversibly inhibits COX-1 and COX-2, connecting prostanoid suppression in inflammatory tissue to analgesia. Neupert’s human whole-blood assays found S-ibuprofen IC50 values of 2.1 μM for platelet COX-1 and 1.6 μM for monocyte COX-2. These system-specific values support nonselective inhibition. Evans measured an unbound S-ibuprofen EC50 of 9.8 μg/L for ex-vivo platelet thromboxane suppression in four healthy men. Design exposure–response experiments around enantiomer, unbound concentration, substrate and sampling time; a clinical pain endpoint tests a different link from the platelet biomarker.
Limits: Neither IC50 nor platelet EC50 is a universal human analgesic threshold.
Questions for this perspective
5 drafted questions in this packet. Targeted additions or replacements for the current guide.
What does the structural experiment directly show?
Established. Orlando’s study resolved S-ibuprofen in murine COX-2 and tested Arg120 and Tyr355 substitutions for effects on binding or inhibition. The deposited 4PH9 structure has 1.81 Å resolution. Selinsky’s ovine COX-1 complex 1EQG offers an isoform comparison. These experiments support a molecular interaction underlying prostanoid inhibition and analgesic pharmacology. They do not measure free drug exposure or target occupancy in human inflammatory tissue. Match species, construct, assay conditions and ligand stereochemistry before combining structural and functional results.
Routing: research / scientist-12.
What experiment would connect exposure to a response?
Probable. A proposed study should quantify unbound S- and R-ibuprofen over time alongside a defined prostanoid output in the selected human cell system. Include vehicle, viability, a mechanistically appropriate comparator and substrate controls. Neupert’s platelet/monocyte assays illustrate why isoform, cell and readout must be specified together. A downstream pain-related phenotype would test an additional link. This is a study-design proposal, not a validated protocol; obtain assay performance, recovery and interference data before interpreting a concentration–response curve as clinical target engagement.
Routing: experiments / role variant.
What quantitative selectivity result can be cited?
Established. Neupert reported S-ibuprofen IC50 values of 2.1 μM for platelet COX-1 and 1.6 μM for monocyte COX-2 in human whole-blood systems. R-ibuprofen had a COX-1 IC50 of 34.9 μM and did not inhibit COX-2 at concentrations up to 250 μM. Those results replace an unspecified claim that no quantitative data exist. They remain assay-specific: substrate, cells, incubation and enantiomer distinguish the experiment from free concentrations in inflammatory tissue and from clinical analgesic potency.
Sources: STEREO
Routing: moa / scientist-04.
How can free exposure be linked to platelet pharmacodynamics?
Established. In four healthy men, Evans related unbound S-ibuprofen to ex-vivo platelet thromboxane generation and estimated an EC50 of 9.8 ± 1.0 μg/L. The studied single doses ranged from 200 to 1,200 mg. This small crossover experiment provides a defined exposure–biomarker relationship, not a universal analgesic concentration threshold. Preserve the microgram-per-liter unit and unbound-enantiomer basis. Total racemate concentrations, tissue prostaglandins and pain scores answer different questions and require their own measurement or validated bridging model.
Sources: PD
Routing: adme / scientist-07.
What evidence separates a new delivery claim from efficacy?
Established. An altered formulation first needs evidence on release, dissolution and systemic exposure. Moore’s review connects faster ibuprofen absorption with improved early analgesic outcomes in defined acute-pain studies, especially dental pain. A new delivery system still requires its own relevant comparator, endpoints and safety assessment. Prespecify time to meaningful relief, rescue medication and duration rather than using Tmax alone as the clinical claim. Existing COX biology supports plausibility, while product-specific human evidence determines whether the proposed benefit is realized.
Routing: development / role variant.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
What outcome needs explaining? — Specify whether the experiment concerns binding, prostanoid synthesis or analgesia. These endpoints sit at different scales. A tissue exposure and biomarker study connects two links; a clinical outcome study tests a further link. ["STRUCT", "PD"]
-
Which targets and pathway? — S-ibuprofen inhibited platelet COX-one and monocyte COX-two with IC-fifty values of two point one and one point six micromolar in Neupert’s whole-blood systems. Preserve cell type, enantiomer and assay conditions when comparing potency. ["STEREO"]
-
What does the experiment establish? — Murine COX-two structure four-P-H-nine resolves S-ibuprofen at one point eight one angstroms. Arg-one-twenty and Tyr-three-fifty-five mutational findings support the binding interpretation. Ovine COX-one structure one-E-Q-G provides a separate isoform experiment. ["STRUCT"]
-
What is not captured by this model? — Compare substrate concentration, incubation, protein environment and readout across assays. R-ibuprofen showed weaker COX-one inhibition and no COX-two inhibition up to two hundred fifty micromolar in Neupert’s experiment. This is a defined assay result rather than a universal inactivity claim. ["STEREO"]
-
What connects target and response? — Evans linked unbound S-ibuprofen with ex-vivo platelet thromboxane suppression in four healthy men. The estimated EC-fifty was nine point eight micrograms per liter. The unit and free-enantiomer basis are essential to reproduce the exposure comparison. ["PD"]
-
What remains unresolved here? — A next experiment could jointly measure unbound enantiomers, prostanoid output and a relevant functional phenotype over time. Include viability, substrate and comparator controls. Distinguish a proposed protocol from validated analytical performance and measured results. ["PD", "STEREO"]
-
What evidence remains necessary? — Cochrane’s postoperative pain analysis provides human efficacy evidence, while CNT and PRECISION address different safety settings. Relate dose, duration, population and endpoint before combining their conclusions into an exposure–benefit–risk model. ["COCHRANE", "CNT", "PRECISION"]
Evidence: Probable for the proposed experiment; other statements Established.
Chemist
Ibuprofen is a chiral arylpropionic acid that reversibly inhibits COX-1 and COX-2, lowering prostanoid production in inflammatory tissue and supporting analgesia. The murine COX-2 complex 4PH9 resolves S-ibuprofen and implicates Arg120 and Tyr355 near its carboxylate; ovine COX-1 structure 1EQG supplies the isoform comparison. Human studies summarized by Evans estimate inversion of 50–60% of the R fraction to S. Water solubility below 1 mg/mL makes dissolution and salt form relevant development variables. Distinguish atomic contacts, stereoselective disposition and clinical formulation performance before proposing a structure–activity improvement.
Limits: Animal-enzyme structures do not measure target occupancy in a patient.
Questions for this perspective
5 drafted questions in this packet. Targeted additions or replacements for the current guide.
How should R-to-S inversion be described?
Established. The marketed acid is a racemate, with S-ibuprofen the principal direct COX inhibitor. Evans summarizes human inversion of approximately 50–60% of the R fraction to S; this is not conversion of 50–60% of the whole racemic dose. Neupert found much weaker R inhibition in the specified assays. Acyl-CoA activation and racemization connect configuration to disposition. Quantitative modeling should use enantiomer-specific exposure and route-specific study results, rather than treating the two enantiomers as independent drugs with fixed equal exposure.
Routing: chemistry / chemist-03.
What pKa should a formulation model use?
Established. PubChem CID 3672 records multiple source-specific values: 4.45 linked to Settimo’s dataset, 4.91 attributed to Sangster, and 5.2 in an older AHFS source. Report provenance and measurement conditions instead of treating one value as an uncontested constant. The prescription label describes water solubility below 1 mg/mL. Ionization, solid form, dissolution and excipients jointly affect release; a calculated pH–solubility curve needs experimentally justified inputs and does not by itself establish bioequivalence or clinical onset.
Routing: formulationScience / chemist-07.
What does a public label establish about manufacture?
Uncertain. The selected manufacturer label establishes identity, strength, excipients and supplied dosage form. A development assessment additionally needs the actual process route, impurity specification, validated analytical methods, stability data and supplier quality records. Those product-specific records should be obtained from the manufacturer’s quality dossier rather than inferred from ibuprofen’s long commercial history. A reproducible synthesis and a qualified finished product are different milestones. No proposed analytical limit, batch release or supplier qualification is certified by the educational page.
Sources: RX
Routing: manufacturing / role variant.
How should the binding contacts be interpreted?
Established. The murine COX-2 study links the acidic group of S-ibuprofen with the channel-entrance region containing Arg120 and Tyr355, supported by structural and mutational evidence. Selinsky’s COX-1 work distinguishes fast reversible inhibitors from slow tight-binding comparators despite related binding-site architectures. A favorable contact is therefore a testable chemical rationale, not a complete structure–activity relationship. Compare a defined analog series with matched potency, kinetics, solubility and exposure measurements before predicting improved clinical analgesia or gastrointestinal safety.
Routing: research / chemist-04.
Which metabolic features matter for chemical design?
Established. Ibuprofen undergoes hepatic oxidation, with CYP2C9 the major oxidative catalyst and CYP2C8/2C19 contributing. The PubChem source records describe hydroxylation of the isobutyl side chain, further oxidation and glucuronide formation. The selected label reports urinary hydroxy and carboxy metabolites and little free parent drug. Distinguish elimination products from a demonstrated activity or toxicity profile for every metabolite. Any proposed soft-spot modification must assess stereoselective disposition, metabolite exposure and clinical safety alongside reduced in-vitro turnover.
Routing: adme / chemist-12.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
What is the chemical problem? — Ibuprofen is a chiral arylpropionic acid supplied here as a racemate. Molecular identity, stereoselective disposition and formulation each influence the interpretation of COX inhibition and analgesic performance. ["RX", "STEREO"]
-
What does this drawing specify? — The carboxylic acid, aromatic group and isobutyl substituent define the chemical scaffold. A bond-line drawing without stereochemical marks does not distinguish R from S. The selected label reports water solubility below one milligram per milliliter. ["RX"]
-
Why does stereochemistry matter? — S-ibuprofen supplies most direct COX inhibition. Human evidence summarized by Evans estimates conversion of fifty to sixty percent of the R fraction to S. The fraction refers to R, not the whole racemic dose; route-specific studies report different disposition quantities. ["STEREO"]
-
What does a binding structure add? — In murine COX-two, the S-ibuprofen carboxylate lies near Arg-one-twenty and Tyr-three-fifty-five. Mutational evidence supports their role. Compare that experiment with the ovine COX-one complex, preserving species, stereochemistry and structure resolution. ["STRUCT"]
-
What structure–activity claim is justified? — Selinsky distinguishes fast reversible inhibitors from slow tight-binding comparators despite related pocket architectures. Design an analog series with matched kinetic and functional assays. A contact change should be tested alongside solubility, selectivity and exposure rather than treated as an automatic clinical improvement. ["MECH", "STRUCT"]
-
Why does formulation matter? — PubChem records source-dependent pKa values of four point four five, four point nine one and five point two. Choose a justified experimental input for a quantitative formulation model. Faster salt absorption has clinical evidence in selected acute-pain settings, but each product needs its own comparison. ["PK", "FAST"]
-
What cannot chemistry alone decide? — CYP-two-C-nine is the principal oxidative catalyst, with other enzymes contributing. Side-chain oxidation and glucuronide formation connect the scaffold to elimination. Assess metabolites, stereoselective exposure and clinical gastrointestinal, renal and cardiovascular outcomes before claiming a superior molecule. ["PK", "RX"]
Evidence: Established; physiology is textbook-level synthesis with experimental sources, not a newly validated animation.
Investor / Diligence Analyst
Ibuprofen reversibly inhibits COX-1 and COX-2 in inflammatory tissues, with established analgesic effects and corresponding gastrointestinal, renal and cardiovascular liabilities. A pooled postoperative NNT of 2.5 at 400 mg anchors efficacy; PRECISION studied 24,081 arthritis patients at increased cardiovascular risk and tested noninferiority. Commercial differentiation requires product-specific evidence on onset, access, brand, channel or outcomes. FDA records distinguish Motrin prescription approval in 1974 from Advil OTC approval in 1984. Audit the proposed comparator, regulatory pathway, intellectual property and net economics separately; a familiar mechanism does not establish a new product’s value.
Limits: Approval dates and prescription volumes do not establish current sales, patent clearance or valuation.
Evidence: Established. Sources: MECH; COCHRANE; PRECISION; REG
Questions for this perspective
5 drafted questions in this packet. Targeted additions or replacements for the current guide.
analyst-03 — What market can be measured?
Established. Ibuprofen spans prescription and OTC channels, which require separate demand measures. ClinCalc estimates 16,850,357 US prescriptions and 10,154,859 patients in 2024, ranking ibuprofen 38th; these figures exclude a complete accounting of OTC purchases. A commercial model should add a dated OTC retail panel and distinguish units, retail sales and manufacturer net revenue. Haleon reporting can contextualize its portfolio, but a company segment is not automatically Advil-only revenue. Define country, channel, pack and data license before computing an addressable market.
Routing: commercial / analyst-03.
analyst-15 — What drives a development budget?
Established. A conventional generic tablet, a faster formulation, a combination and a new indication require different evidence packages. Build the budget from the chosen regulatory pathway, comparator, pharmaceutical development, bioequivalence or clinical studies, manufacturing validation and distribution strategy. Moore’s formulation review identifies measurable onset endpoints for a speed claim. Commission current supplier and study quotes against a defined target product profile; ingredient familiarity cannot price those activities. Brand and channel can affect economics, while clinical differentiation still requires product-specific evidence.
Routing: development / analyst-15.
analyst-16 — What does approval history settle about IP?
Established. Drugs@FDA records Motrin prescription approval on September 19, 1974 and Advil OTC approval on May 18, 1984; the latter application identifies Haleon US Holdings. Generic availability establishes a mature active-ingredient market, not freedom to operate for every formulation, combination, manufacturing process or claim. A current legal review should search the specific proposed product’s patents, exclusivities and jurisdictions. Separate an historical approval date from first sale, current marketing status and patent clearance; the label cannot certify a new product’s freedom to operate.
Sources: REG
Routing: regulation / analyst-16.
analyst-18 — How should price and access be compared?
Established. Separate OTC cash purchases from prescription dispensing and payer reimbursement. A useful price record states strength, formulation, quantity, seller, date and whether shipping, tax or coverage applies. Current patient cost requires a retailer or plan-specific check; prescription volume cannot supply it. Compare identical packs before inferring a premium for faster onset. A development model should distinguish shelf price from manufacturer net revenue, channel fees and promotion costs. Keep expired snapshots out of current-facing copy and retain only clearly labeled historical evidence.
Routing: access / analyst-18.
What belongs in the safety risk ledger?
Established. CNT’s predominantly high-dose evidence estimated ibuprofen major coronary RR 2.22 (95% CI 1.10–4.48), major vascular RR 1.44 (0.89–2.33), and upper gastrointestinal complications RR 3.97 (2.22–7.10). PRECISION supplies a different active-comparator arthritis population and a noninferiority result. Record dose, population, outcome and exposure duration separately for each claim. A short acute-pain tolerability study cannot erase chronic-risk evidence, while high-dose relative risks cannot be converted into a universal OTC absolute risk without an appropriate baseline.
Routing: comparison / role variant.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
What clinical need is addressed? — Define the intended advantage in a specific market: faster meaningful relief, easier use, access or another measurable outcome. Ibuprofen’s established mechanism reduces target uncertainty, but commercial value depends on the proposed product and comparator. ["COCHRANE", "FAST", "REG"]
-
How strong is the mechanism evidence? — Reversible COX-one and COX-two inhibition lowers prostanoid signaling in inflammatory tissue and produces analgesia. Cochrane reports a pooled number needed to treat of two point five at four hundred milligrams for substantial postoperative pain relief. New differentiation needs evidence beyond that ingredient-level result. ["MECH", "COCHRANE"]
-
What is the exposure claim? — Faster salts achieved median Tmax of twenty-nine to thirty-five minutes, compared with ninety minutes for standard acid in Moore’s review. Evaluate meaningful pain relief and rescue medication alongside pharmacokinetics; a product-specific onset claim must match its actual formulation. ["FAST"]
-
What would establish value? — PRECISION enrolled twenty-four thousand eighty-one arthritis patients at increased cardiovascular risk. It supported celecoxib noninferiority at the studied doses. Keep that finding distinct from superiority, occasional OTC use and claims about a new formulation. ["PRECISION"]
-
How should risk be assessed? — Record high-dose cardiovascular and gastrointestinal evidence, kidney interaction risk and contraindications in the product ledger. For economics, separate prescription utilization from OTC retail data and company segment revenue. Current patent clearance, prices and channel terms require product-specific dated evidence. ["CNT", "KIDNEY", "RX", "VOL", "REG"]
Evidence: Established; physiology is textbook-level synthesis with experimental sources, not a newly validated animation.
General
Ibuprofen slows COX-1 and COX-2, enzymes that help make prostaglandins. These chemical signals make pain nerves more sensitive in inflamed tissue. Reducing their production can ease pain and swelling. Standard tablets reach their highest blood level in 1–2 hours. The same signals help protect the stomach lining and maintain blood flow through the kidneys. This shared pathway explains why relief and harm can occur together. A pharmacist can compare the expected benefit and risks using the exact product label, medical history and complete medicine list.
Limits: Feeling better does not establish that the underlying cause has resolved.
Questions for this perspective
2 drafted questions in this packet. Targeted additions or replacements for the current guide.
other-11 — Who developed ibuprofen?
Established. Stewart Adams began a Boots research program in 1953 to find a treatment for rheumatoid arthritis. His work with John Nicholson led to the ibuprofen patent in 1961. FDA records give 1974 for US Motrin approval and 1984 for Advil OTC approval. In 2013, the Royal Society of Chemistry placed plaques at the Nottingham discovery sites. These events link research with prescription use and wider access. Each date describes a particular milestone, rather than the history of every product.
Routing: history / other-11.
Where can I check the evidence behind the animation?
Established. Use the exact product label for directions and warnings, then open the linked study for each number. A structure paper explains a binding experiment. A clinical trial measures outcomes in a defined group of people. The source panel shows which reference supports each claim and separates label dates from medical review. Current prices need a dated seller check. Readers can inspect these different kinds of evidence without assuming that one source supports the whole page.
Sources: RX; OTC; STRUCT; PAIN
Routing: resources / role variant.
Read the revised narration script
Text for review. The current animation and audio have not been rebuilt from this script.
-
Why is ibuprofen used? — Ibuprofen can ease pain and fever by changing signals in the body. A swallowed dose first has to reach the blood. This story follows that path and explains why the same medicine can provide relief and cause unwanted effects. ["RX"]
-
How does the tablet reach the body? — The tablet breaks up, and the drug dissolves in the gut. The dissolved drug then enters blood and reaches tissues. A standard tablet peaks in the blood in one to two hours; the whole tablet does not travel to a sore spot. ["RX"]
-
How does it work? — Ibuprofen slows COX-one and COX-two. These enzymes help tissues make prostaglandins, signals that can make pain nerves more sensitive. Less of the signal can ease pain and swelling. The same pathway helps protect the gut and keep blood flowing through the kidneys. ["MECH", "RX"]
-
When might pain ease? — Pain relief may begin in thirty to sixty minutes, according to a clinical handbook. The drug’s serum half-life is about two hours, which describes how blood levels fall. Neither number tells a person when another dose is safe; that comes from the actual product directions. ["PAT", "RX", "OTC"]
-
What should you know about safety? — A lower pain score shows symptom relief, not proof of healing. The label warns of serious gut bleeding, heart attack and stroke. A pharmacist can check the product and other medicines, including aspirin. New severe symptoms need prompt medical help. ["RX", "OTC"]
Evidence: Established; physiology is textbook-level synthesis with experimental sources, not a newly validated animation.
Trials, pharmacokinetics and questions to ask
Pharmacokinetics at a glance — twelve rows
| Field | Measured value and interpretation | Source |
|---|---|---|
| Absorption | Rapid oral absorption; food slows rate more than extent for selected tablets. | RX |
| Tmax | Standard selected tablet 1–2 hours; peak is not onset. | RX |
| Half-life | Serum 1.8–2 hours; not a standalone dose-interval rule. | RX |
| Protein binding | More than 99%, concentration dependent; saturation described above 20µg/mL in HSDB record. | PK, PubChem/HSDB |
| Distribution | Apparent Vd about 0.1 L/kg; distinguish apparent volume from literal anatomy. | PK, PubChem/DrugBank |
| Metabolism | Hepatic oxidation, chieflyCYP2C9 withCYP2C8/2 C 19 contributions; hydroxyl/carboxyl products and glucuronides. | PK |
| Elimination | 45–79% urinary recovery within 24 hours; mostly metabolites/conjugates, not active unchanged drug. | RX |
| Urinary species | Hydroxy metaboliteA about 25%, carboxyB about 37%, free ibuprofen about 1%, conjugated about 14%; approximate source fractions need not sum to every study's recovery. | RX |
| Stereochemistry | R/S racemate; S principal direct COX inhibitor; human review estimates 50–60% of R fraction inverted to S. | STEREO |
| Solubility | Water solubility below 1 mg/mL; formulation and conditions affect dissolution. | RX |
| Population/interaction effects | Kidney perfusion vulnerability is distinct from metabolism; hepatic disease andCYP2C9 phenotype can affect exposure. Monitor context, not only serum half-life. | RX;PK;CPIC |
| Formulation timing | Review medianTmax standard acid 90 minutes versus arginine/lysine/sodium salts 29–35 minutes;30 PKstudies,1015 participants. | FAST |
Established disposition observations. Limits: the entries combine explicitly identified sources and populations, not a single universal PK experiment.
Efficacy and onset
Established: Cochrane 2009 included 72 studies and 9186 participants. At 400 mg,6475 participants contributed to an NNT of 2.5 (95%CI 2.4–2.6) for at least 50% pain relief over 4–6 hours versus placebo in postoperative pain. At 200 mg,2690 participants contributed to NNT 2.7 (2.5–3.0). Preserve the published pooled decimal estimates; study-specific integer NNT rules do not justify changing them. Source: COCHRANE.
Natural-frequency version: In these studies, treating roughly two to three people with 400 mg instead of placebo produced one extra person with at least half their pain relieved over four to six hours. This does not mean everyone gets relief or that 400 mg is the right dose for each reader.
The Rx label's acute analgesic trials found no additional benefit above 400 mg; arthritis treatment is a different indication and regimen. The Canadian BCEHS handbook estimates oral pain-relief onset at 30–60 minutes; this secondary clinical estimate is distinct from serumTmax and US product directions. Faster-formulation studies provide product-specific evidence rather than a universal claim about all liquid-filled capsules. Sources: RX;FAST;PAT.
Landmark trial — PAIN short-course tolerability
Design: randomized blinded comparison through French general practice; ages 18–75; treatment 1–7 days.8677 randomized,8633 evaluable: ibuprofen 2869,paracetamol 2874,aspirin 2890. Regimens permitted ibuprofen up to 1200 mg/day or the comparators up to 3 g/day; mean ibuprofen treatment 5.6 days. Primary significant-adverse-event definition included moderate/severe events and events leading to reassessment/discontinuation, plus specified missing-intensity handling. Source: PAIN, methods andTableII, visually inspected.
| Outcome | Ibuprofen | Paracetamol | Aspirin |
|---|---|---|---|
| Primary significant events | 392/2869 (13.7%) | 416/2874 (14.5%) | 539/2890 (18.7%) |
| Moderate events | 245/2869 | 294/2874 | See originalTableII |
| Severe events | 100/2869 | 92/2874 | See originalTableII |
Calculated crude risk difference: paracetamol minus ibuprofen=0.81 percentage points; aspirin minus ibuprofen=4.99 points. The first comparison was tested within an equivalence design, with a prespecified 2.7 point margin and one-sided 96.5% confidence bound; do not sell its small numerical difference as proven superiority. For aspirin versus ibuprofen, crude reciprocal difference gives approximately 21 people treated to avoid one primary composite event during the study course, rounded upward from 20.05; this endpoint includes more than serious harm. Source: PAIN; calculation from table counts.
Natural-frequency version: Over this short course, about 14 in 100 people taking ibuprofen had a significant adverse event, compared with about 14 in 100 taking paracetamol and 19 in 100 taking aspirin. These figures do not describe years of treatment or prove that rare serious bleeding cannot occur.
Limits: Boots Healthcare funded the trial; selected short-course participants do not represent every high-risk patient.
Companion trial — Doyle OTC-dose gastrointestinal experience
1246 selected healthy participants; ibuprofen 1200 mg/day for 10 days versus placebo. GI adverse experiences 161/833 (19.33%) versus 67/413 (16.22%); crude difference+3.10 percentage points. The study reported no statistically significant difference. Do not present 1/difference as an established NNH; selected volunteers and short exposure limit rare-event inference. Source: DOYLE, abstract.
Natural-frequency version: Over ten days, about 19 in 100 people taking ibuprofen reported a gut-related problem, compared with 16 in 100 taking placebo. The difference was not statistically clear, and the study cannot prove that bleeding risk is absent.
Long-term and high-dose risk
CNT 2013: Primary evidence was predominantly high-dose ibuprofen 2400 mg/day. Major coronary eventsRR 2.22 (95%CI 1.10–4.48); major vascular eventsRR 1.44 (0.89–2.33); upper GI complicationsRR 3.97 (2.22–7.10). The nonsignificant vascular estimate is not proof of no risk. The paper's widely cited three extra vascular events per 1000 peryear describes coxibs/diclofenac, not a universal ibuprofen absolute estimate. Source: CNT.
Natural-frequency version: The relative risk for major coronary events was about twice the comparison risk in these high-dose trials. A reliable extra-events-per 100 people figure needs the applicable baseline risk and follow-up; this review does not supply one universal number for OTC use.
**PRECISION 2016:**24081 people with osteoarthritis or rheumatoid arthritis and increased cardiovascular risk; mean treatment 20.3 months, follow-up 34.1 months. Mean daily doses: ibuprofen 2045±246 mg,naproxen 852±103 mg,celecoxib 209±37 mg. Primary cardiovascular events: ibuprofen 218 (2.7%),naproxen 201 (2.5%),celecoxib 188 (2.3%). Celecoxib versus ibuprofenHR 0.85 (95%CI 0.70–1.04); noninferiority supported, superiority not established. Celecoxib had fewer renal events than ibuprofen (P=.004) and fewer GI events than ibuprofen (P=.002).68.8%stopped study drug and 27.4%discontinued follow-up. Source: PRECISION, abstract; companion Celebrex label§14.6Table5 supplies randomized denominators: ibuprofen8040,naproxen7969,celecoxib8072. Its ITT table through month30 reports HR0.86 (0.70–1.04), while the publication abstract reports0.85; retain the named analysis rather than silently combining estimates. [VERIFY: reconcile full publication analysis with label table before further effect calculations].
Natural-frequency version: During follow-up, about 3 in 100 people assigned ibuprofen and about 2 in 100 assigned celecoxib had a primary cardiovascular event. The trial supports a specific noninferiority conclusion, not proof that celecoxib prevents more events or that either option is risk-free.
No benefitNNT is claimed from rounded nonsignificant rates. Limits: population, doses and discontinuation constrain transfer to short-course OTC treatment.
Kidney association: Lapi's nested case-control study followed a cohort of 487372 antihypertensive users;2215 AKI cases occurred during mean 5.9 years. Adding an NSAID to a diuretic plusACEinhibitor/ARB was associated withAKI rate ratio 1.31 (1.12–1.53), highest in the first 30 days at 1.82 (1.35–2.46). This observational estimate is not a randomizedNNH or a guarantee that double combinations are safe. Source: KIDNEY.
Natural-frequency version: The three-drug combination was linked to more kidney injury than the comparison treatment. A person's absolute chance depends on kidney health, fluid status and other factors, so the study does not give one reliable extra-cases-per 100 figure for everyone.
Aspirin pharmacodynamic ledger
| Studied regimen | Thromboxane inhibition | Interpretation |
|---|---|---|
| IR aspirin 81 mg plus ibuprofen 400 mg once daily, ibuprofen 2 h before,6 days | 53% | Interaction |
| Ibuprofen 8 h before | 90.7% | Minimized, still observed |
| Ibuprofen 2 h after IR aspirin | 99.2% | No interaction in this regimen |
| Concomitant,15 or 30 minutes after IR aspirin | See label | Interaction; not an equivalent substitute for 2 h |
| IR aspirin followed by ibuprofen 400 mg at 1,7,13 h,10 days | Mean 98.3%; some individuals below 95%,lowest 90.2% | Different multiple-dose experiment |
| Enteric-coated aspirin with ibuprofen 400 mg at 2,7,12 h,6 days | 67% | Interaction |
Source: RX Pharmacodynamics and Drug Interactions; ASPIRIN. These are platelet biomarkers, not clinical-event rates. Patient wording: ask a pharmacist to review prescribed aspirin and the exact pain medicine; do not use a universal self-spacing schedule. This explicitly replaces the audit's oversimplified timing rule.
Guidelines and monitoring
NICE NG 226§1.4: topical NSAID offered for knee OA; consider for other joints; consider oral therapy if topical ineffective/unsuitable with organ, pregnancy and medicine risks assessed; offer gastroprotection while using oral NSAIDs. This is UK OA guidance. AGS Beers 2023: generally avoid chronic oral NSAIDs unless alternatives ineffective and gastroprotection possible; avoid scheduled short-term use with corticosteroids/anticoagulants/antiplatelets unless corresponding exceptions apply;PPI reduces but does not eliminate risk. Avoid atCrCl<30 mL/min; avoid with symptomatic heart failure and use caution with asymptomatic heart failure. Sources: NICE;BEERS.
CPIC 2020 Table 2 applies availableCYP2C9 results: normal/AS 1.5 intermediate recommended starting dose;AS 1 intermediate lowest starting dose with cautious titration/monitoring;poor metabolizer 25–50%of lowest starting dose or alternative, with ibuprofen upward titration only after at least 5 days to steady state. Recommendation strength normalStrong,othersModerate. This clinician guidance is not an individual dose instruction or mandate to test everyone. Source: CPIC.
The Rx label's monitoring is not kidney-only: blood pressure, edema, renal function, GI symptoms, blood counts and chemistry/liver concerns matter according to duration and risk. Serious skin reactions andDRESS require recognition. Sources: RX.
How it was discovered
Stewart Adams began the Boots research program in 1953, seeking a treatment for rheumatoid arthritis. The historical interview describes his collaboration with chemist John Nicholson and the 1961 ibuprofen patent. Their work connects a practical clinical problem with laboratory screening and chemical development. Later regulatory records show a second part of the story: the route from prescription treatment to wider access. The FDA records Motrin approval on September 19,1974 and Advil OTC approval on May 18,1984. These are US approval dates, not dates when every product first reached a pharmacy. In 2013, the Royal Society of Chemistry honored the Nottingham discovery sites with landmark plaques at the Boots and BioCity buildings. The surprising verified detail is that the recognition covered two physical sites, reflecting a discovery program that moved across buildings. Wider access changed who could obtain ibuprofen; it did not remove the need for product directions, interaction checks and safety warnings.
Sources: HIST;REG. [VERIFY: founder manual dates; December 1961 synthesis,1962 grant,1969 UKBrufen launch,1983 UKOTC change,Adams 2019 death and hangover anecdote against original historical records/full interview before adding them to publishable prose.] Do not treat the audit's secondary-history list as fully verified.
Questions to ask your pharmacist
- Which exact ingredient, strength and formulation is in this product?
- Could any of my pain or cold medicines duplicate it?
- Does my aspirin or blood thinner change the choice?
- Do kidney, heart, gut or liver problems affect suitability?
- What changes if I am pregnant or might be pregnant?
- Which product directions apply, and when should persistent symptoms be reviewed?
- Which warning signs need urgent help, and what monitoring is planned?
- How will we judge useful relief and consider another approach if it is not helping?
Sources: RX;OTC. These questions support a consultation; they do not prescribe a regimen.
Myth check and six-question quiz
| Question | Answer and explanation | Source |
|---|---|---|
| Does it act only where it hurts? | No. Systemic exposure reaches multiple tissues; COX effects can help pain and impair protective signaling. | RX;MECH |
| Does more always relieve more? | No. Acute analgesic trials found no extra benefit above 400 mg; this does not replace the actual product directions. | RX;COCHRANE |
| Does food prevent ulcers? | No. Food may help upset and slow absorption; it does not remove bleeding/ulcer risk. AcidTmax 1.34→1.96 h;fast formulation 0.71→1.44 h in the food review. | OTC;FOOD;RX |
| Does less pain prove healing? | No. Reduced sensitization is a symptom effect, not a tissue-repair measurement. | MECH;OTC |
| Is it automatically safe with heart aspirin? | No. Formulation and timing affect platelet interaction; pharmacist review is needed. | RX;ASPIRIN |
| Is late-pregnancy use routine? | No. FDA recommends avoidingNSAIDs from 20 weeks unless specifically advised; if necessary 20–30 weeks,lowest/shortest with fluid monitoring considered beyond 48 h;avoid from 30 weeks because of ductal risk. Prescribed low-dose 81 mgaspirin for certain pregnancy conditions is a separate exception. | FDA;RX |
One shared safety panel — visible in Patient, Pharmacist, Clinician and Nurse views
The prescription label's boxed warning covers heart attack, stroke and serious gut bleeding, ulcers or holes in the gut. These events can be fatal and may occur without warning. The label rules out use around heart bypass surgery, after allergy to ibuprofen, and after aspirin/NSAID reactions such as asthma or hives. Its warnings also rule out use after a serious NSAID skin reaction. Kidney disease, heart failure, past bleeding, pregnancy and other medicines need a professional check. Urgent warning signs include chest pain, one-sided weakness, trouble breathing, blood in vomit, black stools or face/throat swelling. Source: RX;OTC. Full warnings remain linked; this panel is a summary.
About the referenced labels
ManufacturerRx GranulesIndia/GranulesUSA: setid 8804564 c-9 e 1 b-43 c 1-8 b 58-fd 6 ace 645 f 00, SPLv 25,effective 2026-10-07; printedPI revisionJuly 2024. AdvilOTC Haleon: setid 1 a 665 e 64-9 f 30-be 37-4 a 83-38789 f 1 f 1 e 89,SPLv 38,effective 2026-03-12. Editorial source check 2026-10-18. These dates are not clinical review dates. [VERIFY: founder manual label-version/date check.]
Sources
RX; OTC; PK; STEREO; FAST; COCHRANE; PAIN; DOYLE; CNT; PRECISION; KIDNEY; ASPIRIN; FDA; NICE; BEERS; CPIC; HIST; REG; PAT
Reference pack
Source codes in the text resolve to the references below. Retrieval and clinical-review status are distinct.
| ID | Source | Link | Access and scope |
|---|---|---|---|
| RX | Granules India ibuprofen400/600/800mg tablets, SPLv25 effective2026-10-07 | Open | Full HTML/XML retained; boxed warning, PK/PD, contraindications, warnings/interactions read; remaining sections checked as used. |
| OTC | Haleon Advil200mg tablets/caplets, SPLv38 effective2026-03-12 | Open | Full HTML/XML retained; Drug Facts/directions read. Acid formulation, not sodium salt or liquid-filled capsule. |
| MECH | Selinsky2001 PMID11318639; Rome/Lands1975 PMID1061075; Blobaum/Marnett2007 PMID17341061 | Open | First two abstracts read; Blobaum record has no returned abstract. Replace misattributed Rand Doyen2008 PMID18201917, whose abstract was read. |
| STRUCT | Orlando2015 PMID25463020; PDB4PH9 and1EQG | Open | Primary abstract read; both RCSB entries and coordinates retained.4PH9 murineCOX2,1.81Å;1EQG ovineCOX1,2.61Å. Full Orlando XML retrieval failed. |
| STEREO | Neupert1997 PMID9351505; Cheng1994 PMID7937520; Evans2001 PMID11771573; Adams1976 PMID6706 | Open | Neupert/Cheng/Evans abstracts read; Adams metadata only. In-vitro IC50 versus human inversion denominators distinguished. |
| PK | Davies1998 PMID9515184; PubChemCID3672; Mazaleuskaya2015 PMID25502615 | Open | Davies abstract and PubChem provenance-bearing selected fields retained/read. PharmGKB title-only record; full XML failed. PubChem pKa values differ by source. |
| PD | Evans1991 PMID1904749 DOI10.1111/j.1365-2125.1991.tb05500.x | Open | Primary abstract read; four healthy males, unbound S-ibuprofen EC50 9.8±1.0µg/L for ex-vivo plateletTXB2 generation. |
| COCHRANE | Derry2009 PMID19588326 DOI10.1002/14651858.CD001548.pub2; overview2015 PMID26414123 | Open | 2009 abstract read; NNT2.5 (2.4–2.6) at400mg,6475participants,≥50% relief over4–6h. Preserve published decimal pooled NNT. |
| FAST | Moore2014 PMID23969325 DOI10.1016/j.pain.2013.08.013 | Open | Abstract read;30PKstudies1015subjects, salt medianTmax29–35min vs standard90min; clinical evidence also described. |
| FOOD | Moore2015 PMID25784216 DOI10.1111/bcp.12628 | Open | Full XML retained; methods/Table1 read. Multi-drug range1.30–2.80 is not an ibuprofen-only estimate. Linked commentary is not an erratum. |
| CNT | CNT2013 PMID23726390 DOI10.1016/S0140-6736(13)60900-9 | Open | Abstract read, full XML retained; high-dose context and exact outcome-specific RRs required. |
| PRECISION | Nissen2016 PMID27959716 DOI10.1056/NEJMoa1611593 | Open | Primary abstract read;24081,34.1month mean follow-up,20.3month treatment; high discontinuation, noninferiority design and Pfizer funding. |
| PAIN | Moore1999 DOI10.2165/00044011-199918020-00001 | Open | Full primary paper mirror retained; methods, TableII and funding read; TableII page94 visually inspected. Boots-funded. Counts confirmed. |
| DOYLE | Doyle1999 PMID10383524 DOI10.1046/j.1365-2036.1999.00539.x | Open | Abstract read:161/833vs67/413 GI adverse experiences,1200mg/day10days; no blanket no-bleeding-risk claim. |
| KIDNEY | Lapi2013 PMID23299844 DOI10.1136/bmj.e8525 | Open | Abstract read, full XML retained. Nested case-control association,487372cohort; triple combinationRR1.31; not a randomized NNH. |
| ASPIRIN | Catella-Lawson2001 PMID11752357 DOI10.1056/NEJMoa003199 | Open | Abstract read; multiple-dose arm used enteric-coated aspirin. Exact label contains additional immediate-release multiple-dose study. |
| FDA | FDA pregnancy NSAID communication2020-10-15 and aspirin information page | Open | Pregnancy page read through web; local fetch blocked.20/30week distinction,48hour monitoring consideration and prescribed81mg aspirin exception. Aspirin overview alone supplies no universal timing rule. |
| NICE | NICE NG226 osteoarthritis2022,§1.4 | Open | Full page retained; topical/oral/gastroprotection recommendations read. UK setting, not a universal all-pain hierarchy. |
| BEERS | AGS2023 Beers Criteria DOI10.1111/jgs.18372 | Open | University-hosted table PDF retained; oral NSAID, heart-failure and renal thresholds read. Avoid recommendations have exceptions and individual context. |
| PHYS | Clark1991 PMID1904318; Wallace2008 PMID18923189; prostanoid receptor reviewPMC3859365 | Open | Wallace and Clark abstracts read; receptor physiology full XML retained, fever and pathway sections read. Do not treat a review hypothesis as a direct human ibuprofen experiment. |
| REG | Drugs@FDA Motrin NDA017463 and Advil NDA018989 | Open | Official pages inspected:1974-09-19 and1984-05-18 approval. Haleon Advil OTC; Motrin Rx discontinued, explicitly not for safety/effectiveness reasons. |
| HIST | Halford2012 PMID22098129; RSC2013 landmark account | Open | Interview abstract read:1953program,1961Adams/Nicholson patent. RSC landmark account read; full hangover account and precise synthesis/launch milestones remain open. |
| VOL | ClinCalc DrugStats ibuprofen2024 | Open | Retained/read:16850357prescriptions,10154859patients,rank38. Prescription estimates do not measure total OTC sales or brand revenue. |
| CPIC | Theken2020 CYP2C9/NSAID guideline PMID32189324 | Open | Primary PDF retained;Table2 and CYP2C9 phenotype recommendations read. Website redirects to JS-dependent ClinPGx. |
| PAT | MedlinePlus ibuprofen; NHS adult ibuprofen; BCEHS handbook | Open | MedlinePlus retained; US label governs product directions.30–60minute onset checked in BCEHS handbook, distinct fromTmax; MedlinePlus administration/storage/overdose sections checked. |
Twenty-five grouped references. Retrieved2026-10-18. Exact companion PMIDs/PDB IDs identify additional records; evidence files retain responses, hashes and failures. Record discovery does not imply full-text reading. Primary sources override audit shorthand. Clinical review remains pending.
[VERIFY: all approval/launch/label/brand/utilization dates and current price/IP facts manually; original history details and textbook chapters; final comparator labels and source rights.]
Comparator label records are grouped underRX/PK and listed precisely in09; retained HTML and hashes in evidence/final-retrieval.json. Selected sections were read, not every comparator label in full. Physiology source: Narumiya2007,PMC3859365. Secondary onset source: BCEHS handbook. RSC source: 2013landmark account.
[VERIFY: original primary PK source for apparentVd and commercial-use terms for any reproduced DrugBank/PubChem material; factual paraphrase is not a grant to reproduce source tables or graphics.]
Editorial review notes
Marked verification items remain unresolved. Source checks and reading-grade checks do not constitute clinical approval.
Claim-by-claim accuracy check
Existing content
| Existing claim | Disposition | Evidence |
|---|---|---|
| Reversible COX-1/COX-2 inhibition | Preserve; cite biochemical/structure papers, rather than relying only on older tentative label wording. | MECH;STRUCT |
| Kinetics source attributed to “Chen et al.” | Wrong attribution/topic. PMID18201917 is Rand Doyen et al. on phospholipid effects. Replace source mapping, retain historical error only here. | MECH |
| Peak serum levels1–2hours; half-life1.8–2hours | Preserve for selected Rx product. Distinguish peak from onset and next permitted dose. | RX |
| 30–60minute onset | Qualify as secondary handbook estimate; add formulation PK and clinical onset evidence. | FAST;PAT |
| Aspirin interaction depends on timing/formulation; no universal schedule | Correct. Add exact study results and pharmacist action without converting them into a blanket schedule. | RX;ASPIRIN |
| PAIN moderate245/2869vs294/2874; severe100/2869vs92/2874 | Confirmed in original TableII, visually read. Add primary endpoint392/2869vs416/2874; aspirin539/2890. | PAIN |
| Doyle161/833vs67/413 digestive events | Confirmed; retain10days1200mg/day and selected healthy population. | DOYLE |
| Pregnancy20/30weeks and48hour monitoring consideration | Correct; add prescribed81mg aspirin exception with its clinical scope. | RX;FDA |
| Food may help upset, not prevent ulcers/bleeding | Preserve. Add food’s absorption effect without telling everyone to ignore product directions. | RX;OTC;FOOD |
| Higher than400mg no additional acute analgesia | Preserve exact acute-pain scope; not an arthritis dosing ceiling or permission to disregard OTC label. | RX;COCHRANE |
| Duplicate monitoring/effectiveness answer | Replace with distinct functional response and safety-monitoring answers; retain useful existing exact Patient05. | Dossier;RX |
| Four label records and unrevalidated provenance | Consolidate to manufacturerRx and AdvilOTC; record selected-source editorial checks separately from clinical review. | RX;OTC |
Decisions made for the founder
- Audit “ibuprofen400mg three times daily → interaction” collapses different experiments. Label immediate-release aspirin followed by400mg at1,7,13hours for10days had meanTxB2 inhibition98.3%, with some individual values<95% (lowest90.2%). Enteric-coated aspirin with400mg at2,7,12hours for6days had67% inhibition. Once-daily400mg two hours after immediate-release81mg aspirin showed99.2%; two hours before53%; eight hours before90.7%. Preserve regimen, endpoint and individual variability. Do not publish the audit’s universal “aspirin first, wait two hours” self-dosing rule.
- Audit “kidney, not liver, is the organ to watch” is too narrow: the label also describes hepatic injury and periodic CBC/chemistry for long use. Monitor by risk and symptoms, not one organ alone.
- Audit “the only premium lever is speed” overstates evidence. Formulation, combinations, brand and channel require their own efficacy, safety, access and IP evidence. No categorical commercial exclusivity claim.
- Food review’s1.30–2.80Tmax ratio and44–85%Cmax range cover multiple analgesics. Its Table1 separately reports ibuprofen acid1.34→1.96hours (147%) and fast-acting0.71→1.44hours (203%); Cmax78% and73% of fasted values respectively. Preserve this scope.
- Preserve pooled Cochrane NNT2.5 with95%CI2.4–2.6 instead of silently rounding the published meta-analytic estimate; whole-person explanation can say roughly one extra responder per two to three treated. Do not infer a placebo response by subtracting this pooled effect from a separately pooled treated rate.
- CNT’s “three additional vascular events per1000peryear” refers to coxibs/diclofenac, not a directly measured universal ibuprofen absolute risk. Ibuprofen relative effects need baseline-risk context; PRECISION supplies its own absolute trial rates.
- Generic availability does not establish freedom to operate for every new formulation/combination. Approval dates are not first-sale dates or blanket patent expiry dates.
- R-ibuprofen is weaker atCOX1 and lackedCOX2 inhibition to250µM in Neupert’s assay, not inactive at every target/concentration. The50–60% inversion estimate applies to the R fraction, not the entire racemic dose; Cheng reports different route-specific quantities.
- PubChem lists multiple source-specific pKa values (4.45,4.91,5.2); do not call one an uncontested exact constant. Use provenance and conditions for quantitative modeling.
- No new safety-relevant live error missed by the audit has been established. Corrections above concern audit proposals or already-identified content gaps.
Source links
RX; OTC; MECH; STRUCT; PAIN; DOYLE; FOOD; COCHRANE; CNT; PRECISION; ASPIRIN; STEREO; PK; FDA
[VERIFY: full claim alignment after all drafts, current label dates, clinical review, role routing and final safety-panel visibility.] [FOUNDER TO SUPPLY: actual reviewing pharmacist/clinician identity, credentials, date and disposition.]
Plain-language checks
Method
Before introductions are exact strings from raw/js/medicine-moa-answer.js; after text is03. Script baselines are the full original caption bodies in data/ibuprofen-story-profiles.md, not a guessed memory of the drug. Grades exclude headings, source labels and shared footer. The Patient/General script target is6–8 under the ibuprofen-specific rule; General introduction target8–10 remains. Naturally simple Caregiver prose below6 is retained rather than made harder.
| Role | Introduction before FK | After FK | Script before FK | After FK | Script words before→after |
|---|---|---|---|---|---|
| Patient | 12.57 | 6.40 | 8.75 | 6.43 | 737→591 |
| Caregiver | 14.57 | 5.06 | 8.06 | 5.45 | 262→217 |
| General | 14.06 | 8.44 | 7.55 | 6.31 | 230→208 |
Patient — actual before
Ibuprofen temporarily slows COX-1 and COX-2, enzymes that help your body make prostaglandins—chemical signals involved in pain, fever and inflammation. Making fewer of these signals can ease symptoms, but feeling better does not necessarily mean their cause has been treated.
Patient — revised
Ibuprofen slows two enzymes, COX-1 and COX-2. In sore tissue, this lowers signals that make pain nerves more sensitive. Pain and swelling can ease. A standard tablet reaches its peak blood level in 1–2 hours. The same pathway helps protect the gut and keep blood flowing through the kidneys. The prescription label warns of serious gut bleeding, heart attack and stroke. It rules out use around heart bypass surgery and after certain aspirin or NSAID allergy reactions. A pharmacist can check the exact product and your other medicines.
Caregiver — actual before
Ibuprofen temporarily reduces COX enzyme activity, lowering prostaglandin signals that contribute to pain, fever and inflammation. This may help the person you care for feel more comfortable, but symptom relief alone does not show that an illness or injury has resolved.
Caregiver — revised
Ibuprofen slows COX-1 and COX-2 in tissues, reducing signals that make pain nerves more sensitive. The person you help may move or rest with less pain. A standard tablet peaks in the blood in 1–2 hours. Keep a record of the product, strength and time given. Check cold remedies for the same drug. Adult tablets and child liquids have different directions. Ask a pharmacist to check aspirin, blood thinners and other pain drugs. Watch for black stools, blood in vomit or trouble breathing; these signs need urgent help.
General — actual before
Ibuprofen temporarily slows the COX enzymes that help turn arachidonic acid into prostaglandin signals. Reducing these signals can ease pain, fever and inflammation, but does not necessarily remove their underlying cause.
General — revised
Ibuprofen slows COX-1 and COX-2, enzymes that help make prostaglandins. These chemical signals make pain nerves more sensitive in inflamed tissue. Reducing their production can ease pain and swelling. Standard tablets reach their highest blood level in 1–2 hours. The same signals help protect the stomach lining and maintain blood flow through the kidneys. This shared pathway explains why relief and harm can occur together. A pharmacist can compare the expected benefit and risks using the exact product label, medical history and complete medicine list.
FAQ pass
Saved-file validation checks every new FAQ answer against60–110words and checks Patient/Caregiver≤8,General8–10. The aspirin answer preserves regimen limitations while replacing a universal self-spacing rule. Monitoring now distinguishes symptom response from harm detection. Exact numbers and adverse-event meanings were retained; short sentences replace dense framing.
Final human checks
[VERIFY: comprehension and teach-back with representative readers; final merged text, not just these fragments; warning visibility, speech pronunciation and captions.] [FOUNDER TO SUPPLY: actual qualified reviewer and native-language review records.]
Changes and acceptance checks
Changes and reasons —2026-10-18
-00–02: read full audit/dossier/scripts; verified manufacturerRx and brandedOTC labels, retained evidence and corrected audit shorthand. Source facts override unsupported proposed edits. -03: ten 60–120 word introductions; target,tissue,effect,decision,Limits and linked sources. ValidJS answers/sources fragment accompanies the prose. -04:43 role-specific targeted FAQs; all 29 raw topics lacking profiles gain a role variant, and weak exact answers receive replacements. TenMOA variants and required history/aspirin/analyst records included in validJSON fragments. Existing good answers remain a merge requirement. -05: twelvePKrows, efficacy,PAIN,Doyle,CNT,PRECISION,kidney study,aspirinPD ledger,guidelines,152-word history,eight consultation questions,six misconception questions,shared safety and provenance panels. -06: actual before/after grades and wordcounts; Patient/Caregiver/General checks. -07: all 62 original caption slots rewritten across ten roles; one shared limits footer. Patient 737→591 words,FK 8.75→6.43; General 230→208,7.55→6.31;Caregiver 262→217,8.06→5.45. -08: seven technical-role introductions in Kannada and Marathi plus twelve-term glossary in English,Spanish,Hindi,Kannada,Marathi. Draft status and locale scope explicit; no native approval claimed. -09: six-drug comparison, two extra visual chapters and reading-page integration instructions.
Numerical change ledger
| Numbers added or clarified | Source and scope |
|---|---|
| Tmax 1–2 h,half-life 1.8–2 h,urinary 45–79%/24 h,A 25%,B 37%,free 1%,conjugated 14%,solubility<1 mg/mL | RX Clinical Pharmacology/Description |
| Binding>99%,saturation>20µg/mL,Vd 0.1 L/kg,pKa 4.45/4.91/5.2 | PK PubChem provenance-bearing records; source-specific estimates |
| R-fraction 50–60%inversion;SIC 50COX1/2=2.1/1.6µM,RCOX1=34.9,COX2noinhibition≤250µM | STEREO human review/whole-blood assay |
| UnboundS EC 50 9.8±1.0µg/L,fourmen,doses 200–1200 mg | PD; platelet biomarker, not analgesic threshold |
| PDB4PH9 1.81Å,1EQG2.61Å | STRUCT; mouseCOX2/sheepCOX1 |
| CochraneNNT 2.5(2.4–2.6),400 mg,6475;200 mgNNT 2.7(2.5–3),2690;72 studies 9186 | COCHRANE; pooled outcome≥50%relief 4–6 h |
| No added acute analgesia>400 mg;OTC 200 mg 4–6 h,maxsix/24 h,age 12;10 daypain/3 dayfever reassessment | RX;OTC; exact indication/product scope |
| SaltsTmax 29–35 vs 90 min,30 PKstudies 1015;onset 30–60 min | FAST;PATBCEHS secondary estimate |
| Foodacid 1.34→1.96 h,fast 0.71→1.44 h;Cmax 78%/73%inaccuracyrecord | FOOD Table 1; not multi-drug range misapplied to ibuprofen |
| PAIN 8677 random 8633 evaluable;392/2869,416/2874,539/2890;moderate 245/294,severe 100/92;1–7 d 1200 mgvs 3 g;age 18–75;5.6 dmean | PAIN primaryTableII/methods;crude differences 0.81 and 4.99 points,NNT 21 for composite versus aspirin |
| Doyle 161/833 vs 67/413;1246,10 d 1200 mg;difference 3.10 points | DOYLE; nonsignificant, no definitiveNNH |
| CNT 2400 mg,RR 2.22/1.44/3.97 withCIs | CNT; high-dose endpoints separated |
| PRECISION 24081,20.3/34.1 months,doses 2045/852/209 mg,events 218/201/188,rates 2.7/2.5/2.3,HR.85(.70–1.04),68.8%/27.4%discontinuation | PRECISION abstract; companionlabel denominators 8040/7969/8072 andHR.86 separately attributed |
| Lapi 487372,2215,5.9 years,RR 1.31(1.12–1.53),first 30 days 1.82(1.35–2.46) | KIDNEY observational cohort/nestedcasecontrol |
| Aspirin 81 mg/ibu 400 mg schedules,53/90.7/99.2/98.3/67%inhibition | RX Pharmacodynamics; preserveIR/EC,frequency,time,individual variation |
| Pregnancy 20/30 weeks,48 hmonitoring,81 mgexception | FDA;RX |
| BeersCrCl 30;CPICAS 1/1.5,poor 25–50%,5 days | BEERS;CPIC guideline scopes |
| 1953,1961,1974-09-19,1984-05-18,2013 | HIST;REG; manual verification pending |
| 2024 prescriptions 16850357,patients 10154859,rank 38 | VOL; prescription estimates, notOTCsales |
| Comparator half-lives 12–17 h,2 h,11 h,20 min,2–3 h and intervals | Selected comparator labels linked 09;aspirin/APAPPKfrom explicit combination labels |
| SPLv 25/2026-10-07,printedJuly 2024;OTCv 38/2026-03-12;check 2026-10-18 | Retained labelXML plus printedPI; not clinical review dates |
Decisions made for the founder
- Replace audit's universal aspirin-spacing recommendation with exact regimen evidence and pharmacist review. A separateIR/TID study averaged 98.3%;theEC/TID study 67%. No unsupported universal rule.
- Remove misattributed kinetics author from publishable data; keep its name only in historical accuracy findings so the correction is traceable.
- Correct the audit's default-topic count to 29. Keep good existing Gen 1 variants; no blanket replacement with generic text.
- Keep pooledNNT 2.5; use integer rounding only for a clearly labeled count-derivedNNT. Correct crude risk arithmetic using original counts.
- Replace unverified historical anecdotes with a verified two-site landmark detail. Deferred chronology remains explicitly marked, not invented.
- Correct kidney-only monitoring, food-range attribution and exclusive commercial-lever language. Retain PK/PD/clinical endpoint distinctions.
- Natural Caregiver grade below 6 accepted rather than increasing difficulty. Patient/General scripts 6–8;General intro 8–10.
- Kannada/Marathi technical introductions are complete draft locale content; audio/full-script localization remains explicitly outside this introduction fragment's release claim.
- LabelPI revision,SPLeffective date,editorialcheck and medicalreview are distinct. SelectedCelebrexPRECISION table and publicationHR differ; name the analysis rather than merging them.
Acceptance checklist
| Audit requirement | Result |
|---|---|
| TenMOA 60–120 words,target,tissue,effect,Limits | PASS saved-file checks |
| Correct source attribution;oneRx/oneOTCibuprofen anchor | PASS draft data; historical error retained only in audit trail |
| NNT,ceiling,Tmax,CNT,PRECISION,kidney ratio | PASS with endpoint/source context |
| Aspirin rule and exceptions | PASS as evidence-supported adaptation; universal rule rejected with reasons |
| History and analyst factual content | PASS verified chronology and actionable evidence; unverified historical details remain marked |
| Ten revised scripts,at mostoneLimits/caption,sharedfooter | PASS all 62 slots; no repeated caption disclaimers |
| Patient/Caregiver reading level | PASS ceiling 8; naturally lowerCaregiver accepted;General script 6–8 |
| Every number traceable;openmarkers consolidated | PASS source ledger; final consolidation follows |
| Twochapters,classcomparison,quiz,guidelines,translations | PASS editorial drafts; native/visual/clinical implementation gates unperformed |
| Clinical review/live deployment | NOT PERFORMED; no approval or publication claimed |
Open items
[VERIFY: full historical chronology and hangover interview; founder manual regulatory/label/marketdates; fullPRECISION analysis reconciliation; final structural annotation and figure rights; textbook chapter numbers; comparator formulation-specificPK; final merged role routing, safety panels, glossary, comprehension, visual/audio/accessibility and locale QA; fresh prices/IP/marketdata for any commercial claim.] [FOUNDER TO SUPPLY: qualified clinical reviewer identity,credentials,date and disposition; Kannada/Marathi native health-professional review and other-language glossary review.] No substantiated safety-relevant error in live content missed by the audit was established. All outputs remain drafts. Next: levothyroxine.
Translation draft — native clinical review pending
Scope and review status
Kannada and Marathi technical introductions for all seven professional/learning perspectives. These replace generic patient prose presented under technical role labels. They are localized, role-specific adaptations of03, not certified translations or replacements for the complete English narration. Keep the English version available and label the locale scope honestly until full audio/script localization is reviewed. Source numbers, units, endpoints and warnings must remain visible.
Translation status: Draft — native-speaking health-professional review pending. No reviewer identity or sign-off is claimed.
Kannada
Pharmacist
ಐಬುಪ್ರೊಫೆನ್ COX-1 ಮತ್ತು COX-2 ಅನ್ನು ಹಿಂತಿರುಗಿಸಬಹುದಾದ ರೀತಿಯಲ್ಲಿ ತಡೆಯುತ್ತದೆ. ಉರಿಯೂತ ಇರುವ ಅಂಗಾಂಶದಲ್ಲಿ ಪ್ರೊಸ್ಟಾನಾಯ್ಡ್ ಉತ್ಪಾದನೆ ಕಡಿಮೆಯಾಗುವುದರಿಂದ ನೋವು ಕಡಿಮೆಯಾಗುತ್ತದೆ. ಶಸ್ತ್ರಚಿಕಿತ್ಸೆಯ ನಂತರದ ನೋವಿನ ಅಧ್ಯಯನಗಳಲ್ಲಿ 400 mg ಗೆ NNT 2.5 ಆಗಿತ್ತು; ಇದು 4–6 ಗಂಟೆಗಳಲ್ಲಿ ಕನಿಷ್ಠ 50% ನೋವು ನಿವಾರಣೆಯ ಫಲಿತಾಂಶ. ಆಸ್ಪಿರಿನ್ನ ರೂಪ ಮತ್ತು ಬಳಕೆಯ ವೇಳಾಪಟ್ಟಿಯನ್ನು ಪ್ರತ್ಯೇಕವಾಗಿ ಪರಿಶೀಲಿಸಿ. ಲೇಬಲ್ನಲ್ಲಿ ಹೃದಯಾಘಾತ, ಪಾರ್ಶ್ವವಾಯು ಮತ್ತು ಗಂಭೀರ ಜೀರ್ಣಾಂಗ ರಕ್ತಸ್ರಾವದ ಬಾಕ್ಸ್ ಎಚ್ಚರಿಕೆಗಳಿವೆ. ಅತಿಸೂಕ್ಷ್ಮತೆ, ಆಸ್ಪಿರಿನ್/NSAID ಅಲರ್ಜಿ ಪ್ರತಿಕ್ರಿಯೆ, CABG ಶಸ್ತ್ರಚಿಕಿತ್ಸೆಯ ಸುತ್ತಲಿನ ಬಳಕೆ ಮತ್ತು ಹಿಂದಿನ ಗಂಭೀರ NSAID ಚರ್ಮದ ಪ್ರತಿಕ್ರಿಯೆಗಳನ್ನು ಪರಿಶೀಲಿಸಬೇಕು.
ಮಿತಿಗಳು: ಇದು ವೈಯಕ್ತಿಕ ಚಿಕಿತ್ಸಾ ಸಲಹೆಯಲ್ಲ. ಮೂಲ ಅಧ್ಯಯನದ ಸಂದರ್ಭ ಮತ್ತು ಸಂಪೂರ್ಣ ಉತ್ಪನ್ನ ಎಚ್ಚರಿಕೆಗಳು ಅನ್ವಯಿಸುತ್ತವೆ.
Evidence: Established within cited study scope. Sources: RX; MECH; COCHRANE; ASPIRIN
Clinician
ಐಬುಪ್ರೊಫೆನ್ನ COX-1/COX-2 ನಿರೋಧನವು ಉರಿಯೂತದ ಅಂಗಾಂಶದಲ್ಲಿ ಪ್ರೊಸ್ಟಾನಾಯ್ಡ್ ಉತ್ಪಾದನೆಯನ್ನು ಕಡಿಮೆ ಮಾಡಿ ನೋವು ಮತ್ತು ಕಾರ್ಯಕ್ಷಮತೆಯನ್ನು ಸುಧಾರಿಸಬಹುದು. ಹೆಚ್ಚಿನ ಡೋಸ್ ಅಧ್ಯಯನಗಳಲ್ಲಿ ಪ್ರಮುಖ ಕೊರೊನರಿ ಘಟನೆಗಳ RR 2.22; ಪ್ರಮುಖ ರಕ್ತನಾಳ ಘಟನೆಗಳ RR 1.44 ಗೆ ವಿಶ್ವಾಸ ಮಿತಿ 1 ಅನ್ನು ಒಳಗೊಂಡಿದೆ. ಇವು ಒಂದೇ ಫಲಿತಾಂಶವಲ್ಲ. ಮೂಲ ಹೃದಯ, ಜೀರ್ಣಾಂಗ ಮತ್ತು ಮೂತ್ರಪಿಂಡದ ಅಪಾಯವನ್ನು ಪರಿಗಣಿಸಬೇಕು. ಗಂಭೀರ ಹೃದಯರಕ್ತನಾಳ ಮತ್ತು ಜೀರ್ಣಾಂಗ ಘಟನೆಗಳ ಬಾಕ್ಸ್ ಎಚ್ಚರಿಕೆಗಳನ್ನು ಉಳಿಸಿ. ಅಲರ್ಜಿ, CABG ಸಂದರ್ಭ ಮತ್ತು ಹಿಂದಿನ ಗಂಭೀರ NSAID ಚರ್ಮದ ಪ್ರತಿಕ್ರಿಯೆಗಳನ್ನು ಹೊರತುಪಡಿಸಬೇಕು. NICE ಅಸ್ಥಿಸಂಧಿವಾತ ಮಾರ್ಗದರ್ಶನದಲ್ಲಿ ಸೂಕ್ತ ಸಂದರ್ಭಗಳಲ್ಲಿ ಸ್ಥಳೀಯ NSAID ಗೆ ಆದ್ಯತೆ ಇದೆ.
ಮಿತಿಗಳು: ಇದು ವೈಯಕ್ತಿಕ ಚಿಕಿತ್ಸಾ ಸಲಹೆಯಲ್ಲ. ಮೂಲ ಅಧ್ಯಯನದ ಸಂದರ್ಭ ಮತ್ತು ಸಂಪೂರ್ಣ ಉತ್ಪನ್ನ ಎಚ್ಚರಿಕೆಗಳು ಅನ್ವಯಿಸುತ್ತವೆ.
Evidence: Established within cited study scope. Sources: RX; MECH; CNT; NICE
Nurse
ಐಬುಪ್ರೊಫೆನ್ ಅಂಗಾಂಶಗಳಲ್ಲಿ COX-1 ಮತ್ತು COX-2 ಅನ್ನು ತಡೆಯುವುದರಿಂದ ಪ್ರೊಸ್ಟಾಗ್ಲ್ಯಾಂಡಿನ್ ಉತ್ಪಾದನೆ ಮತ್ತು ನೋವು ಅಥವಾ ಜ್ವರ ಕಡಿಮೆಯಾಗಬಹುದು. ನೀಡುವ ಮೊದಲು ನೋವಿನ ಮಟ್ಟ, ಕಾರ್ಯದ ಗುರಿ, ಔಷಧದ ರೂಪ ಮತ್ತು ಕೊನೆಯ ಡೋಸ್ ದಾಖಲಿಸಿ. ಸಾಮಾನ್ಯ ಮಾತ್ರೆಯ ರಕ್ತದ ಗರಿಷ್ಠ ಮಟ್ಟ 1–2 ಗಂಟೆಗಳಲ್ಲಿ ಬರುತ್ತದೆ; ಇದು ಎಲ್ಲರಿಗೂ ಅನ್ವಯಿಸುವ ಮರುಮೌಲ್ಯಮಾಪನ ಸಮಯವಲ್ಲ. ರಕ್ತಸ್ರಾವ, ನೀರಿನ ಕೊರತೆ, ಮೂತ್ರದ ಪ್ರಮಾಣ ಮತ್ತು ರಕ್ತದೊತ್ತಡದ ಬದಲಾವಣೆಗಳನ್ನು ಆರೈಕೆ ಯೋಜನೆಯಂತೆ ಗಮನಿಸಿ. ಬಾಕ್ಸ್ ಎಚ್ಚರಿಕೆಗಳಲ್ಲಿ ಗಂಭೀರ ಹೃದಯರಕ್ತನಾಳ ಮತ್ತು ಜೀರ್ಣಾಂಗ ಘಟನೆಗಳಿವೆ. ಅಲರ್ಜಿ, CABG ಮತ್ತು ಹಿಂದಿನ ಗಂಭೀರ NSAID ಚರ್ಮದ ಪ್ರತಿಕ್ರಿಯೆಯ ಇತಿಹಾಸವನ್ನು ಪರಿಶೀಲಿಸಿ.
ಮಿತಿಗಳು: ಇದು ವೈಯಕ್ತಿಕ ಚಿಕಿತ್ಸಾ ಸಲಹೆಯಲ್ಲ. ಮೂಲ ಅಧ್ಯಯನದ ಸಂದರ್ಭ ಮತ್ತು ಸಂಪೂರ್ಣ ಉತ್ಪನ್ನ ಎಚ್ಚರಿಕೆಗಳು ಅನ್ವಯಿಸುತ್ತವೆ.
Evidence: Established within cited study scope. Sources: RX; OTC; MECH
Student
COX-1 ಮತ್ತು COX-2 ಅರಾಕಿಡೋನಿಕ್ ಆಮ್ಲದಿಂದ ಪ್ರೊಸ್ಟಾನಾಯ್ಡ್ ಪೂರ್ವಗಾಮಿಗಳನ್ನು ನಿರ್ಮಿಸುವ ಮಾರ್ಗದಲ್ಲಿ ಕೆಲಸ ಮಾಡುತ್ತವೆ. ಐಬುಪ್ರೊಫೆನ್ ಈ ಹಂತವನ್ನು ಹಿಂತಿರುಗಿಸಬಹುದಾದ ರೀತಿಯಲ್ಲಿ ತಡೆಯುತ್ತದೆ. ಉರಿಯೂತದ ಅಂಗಾಂಶದಲ್ಲಿ ಕಡಿಮೆ ಪ್ರೊಸ್ಟಾಗ್ಲ್ಯಾಂಡಿನ್ ಸಂಕೇತವು ನೋವಿನ ಸಂವೇದನಾಶೀಲತೆಯನ್ನು ಕಡಿಮೆ ಮಾಡುತ್ತದೆ. ಜ್ವರದ ಮಾರ್ಗ ಮತ್ತು ಹೊಟ್ಟೆ ಹಾಗೂ ಮೂತ್ರಪಿಂಡದ ರಕ್ಷಣಾತ್ಮಕ ಮಾರ್ಗಗಳನ್ನು ಬೇರೆ ಬೇರೆ ನೋಡಬೇಕು. 1.8–2 ಗಂಟೆಗಳ ಸೀರಮ್ ಅರ್ಧಾಯುಷ್ಯವು ಔಷಧದ ವಿಲೇವಾರಿಯನ್ನು ವಿವರಿಸುತ್ತದೆ; ಅದು ಡೋಸ್ ನಡುವಿನ ಅಂತರವನ್ನು ನಿರ್ಧರಿಸುವುದಿಲ್ಲ. ಆಸ್ಪಿರಿನ್ನ ಶಾಶ್ವತ ಪ್ಲೇಟ್ಲೆಟ್ COX ಅಸೆಟಿಲೇಶನ್ ಮತ್ತು ಐಬುಪ್ರೊಫೆನ್ನ ಹಿಂತಿರುಗಿಸಬಹುದಾದ ಬಂಧನವನ್ನು ಹೋಲಿಸಿ.
ಮಿತಿಗಳು: ಇದು ವೈಯಕ್ತಿಕ ಚಿಕಿತ್ಸಾ ಸಲಹೆಯಲ್ಲ. ಮೂಲ ಅಧ್ಯಯನದ ಸಂದರ್ಭ ಮತ್ತು ಸಂಪೂರ್ಣ ಉತ್ಪನ್ನ ಎಚ್ಚರಿಕೆಗಳು ಅನ್ವಯಿಸುತ್ತವೆ.
Evidence: Established within cited study scope. Sources: RX; MECH; PHYS; ASPIRIN
Scientist
ನೋವು ನಿವಾರಣೆಯ ಯಾಂತ್ರಿಕತೆಯನ್ನು ಅಧ್ಯಯನ ಮಾಡುವಾಗ COX-1/COX-2 ನಿರೋಧನ, ಅಂಗಾಂಶದ ಔಷಧ ಸಾಂದ್ರತೆ ಮತ್ತು ಪ್ರೊಸ್ಟಾನಾಯ್ಡ್ ಫಲಿತಾಂಶಗಳನ್ನು ಪ್ರತ್ಯೇಕವಾಗಿ ಅಳೆಯಬೇಕು. Neupert ಅವರ ಮಾನವ ಸಂಪೂರ್ಣ ರಕ್ತ ಪರೀಕ್ಷೆಯಲ್ಲಿ S-ಐಬುಪ್ರೊಫೆನ್ IC50 ಪ್ಲೇಟ್ಲೆಟ್ COX-1 ಗೆ 2.1 μM ಮತ್ತು ಮೊನೊಸೈಟ್ COX-2 ಗೆ 1.6 μM ಆಗಿತ್ತು. Evans ಅವರ ನಾಲ್ಕು ಆರೋಗ್ಯವಂತ ಪುರುಷರ ಅಧ್ಯಯನದಲ್ಲಿ ಬಂಧಿತವಲ್ಲದ S-ಐಬುಪ್ರೊಫೆನ್ EC50 9.8 μg/L ಆಗಿತ್ತು; ಫಲಿತಾಂಶವು ದೇಹದ ಹೊರಗೆ ಅಳೆಯಲಾದ ಪ್ಲೇಟ್ಲೆಟ್ ಥ್ರಾಂಬಾಕ್ಸೇನ್ ಉತ್ಪಾದನೆ. ಈ ಮೌಲ್ಯಗಳನ್ನು ಮಾನವ ನೋವು ನಿವಾರಣೆಯ ಸಾರ್ವತ್ರಿಕ ಮಿತಿಯಾಗಿ ಬಳಸಬಾರದು. ಎನಾಂಟಿಯೊಮರ್, ಸಬ್ಸ್ಟ್ರೇಟ್ ಮತ್ತು ಸಮಯವನ್ನು ದಾಖಲಿಸಿ.
ಮಿತಿಗಳು: ಇದು ವೈಯಕ್ತಿಕ ಚಿಕಿತ್ಸಾ ಸಲಹೆಯಲ್ಲ. ಮೂಲ ಅಧ್ಯಯನದ ಸಂದರ್ಭ ಮತ್ತು ಸಂಪೂರ್ಣ ಉತ್ಪನ್ನ ಎಚ್ಚರಿಕೆಗಳು ಅನ್ವಯಿಸುತ್ತವೆ.
Evidence: Established within cited study scope. Sources: STEREO; PD; MECH
Chemist
ಐಬುಪ್ರೊಫೆನ್ ಒಂದು ಕೈರಲ್ ಅರೈಲ್ಪ್ರೊಪಿಯಾನಿಕ್ ಆಮ್ಲ. ಇದು COX-1/COX-2 ಅನ್ನು ಹಿಂತಿರುಗಿಸಬಹುದಾದ ರೀತಿಯಲ್ಲಿ ತಡೆದು ಉರಿಯೂತದ ಅಂಗಾಂಶದಲ್ಲಿ ಪ್ರೊಸ್ಟಾನಾಯ್ಡ್ ಉತ್ಪಾದನೆ ಮತ್ತು ನೋವನ್ನು ಕಡಿಮೆ ಮಾಡುತ್ತದೆ. ಮೌಸ್ COX-2 ರ 4PH9 ರಚನೆಯಲ್ಲಿ S-ಐಬುಪ್ರೊಫೆನ್ ಮತ್ತು ಅದರ ಕಾರ್ಬಾಕ್ಸಿಲೇಟ್ ಸಮೀಪದ Arg120 ಹಾಗೂ Tyr355 ಸಂಬಂಧಗಳು ಕಾಣುತ್ತವೆ. ಕುರಿಯ COX-1 ರ 1EQG ಬೇರೆ ಐಸೋಫಾರ್ಮ್ ಹೋಲಿಕೆಯನ್ನು ಒದಗಿಸುತ್ತದೆ. ಮಾನವರಲ್ಲಿ R ಭಾಗದ ಸುಮಾರು 50–60% S ರೂಪಕ್ಕೆ ಪರಿವರ್ತನೆಯಾಗುತ್ತದೆ ಎಂದು ವಿಮರ್ಶೆ ಹೇಳುತ್ತದೆ. ನೀರಿನಲ್ಲಿ ದ್ರಾವಣೀಯತೆ 1 mg/mL ಗಿಂತ ಕಡಿಮೆ. ಬಂಧನ, ಸ್ಟೀರಿಯೊರಸಾಯನಶಾಸ್ತ್ರ ಮತ್ತು ಔಷಧ ರೂಪದ ಕಾರ್ಯಕ್ಷಮತೆಯನ್ನು ಪ್ರತ್ಯೇಕವಾಗಿ ಪರೀಕ್ಷಿಸಬೇಕು.
ಮಿತಿಗಳು: ಇದು ವೈಯಕ್ತಿಕ ಚಿಕಿತ್ಸಾ ಸಲಹೆಯಲ್ಲ. ಮೂಲ ಅಧ್ಯಯನದ ಸಂದರ್ಭ ಮತ್ತು ಸಂಪೂರ್ಣ ಉತ್ಪನ್ನ ಎಚ್ಚರಿಕೆಗಳು ಅನ್ವಯಿಸುತ್ತವೆ.
Evidence: Established within cited study scope. Sources: STRUCT; STEREO; RX; MECH
Investor / Diligence Analyst
ಐಬುಪ್ರೊಫೆನ್ನ COX-1/COX-2 ನಿರೋಧನವು ಉರಿಯೂತದ ಅಂಗಾಂಶದಲ್ಲಿ ಪ್ರೊಸ್ಟಾನಾಯ್ಡ್ ಸಂಕೇತಗಳನ್ನು ಕಡಿಮೆ ಮಾಡಿ ಸ್ಥಾಪಿತ ನೋವು ನಿವಾರಣೆಯನ್ನು ನೀಡುತ್ತದೆ. ಶಸ್ತ್ರಚಿಕಿತ್ಸೆಯ ನಂತರದ ನೋವಿಗೆ 400 mg ನಲ್ಲಿ ಸಂಯೋಜಿತ NNT 2.5 ಒಂದು ಪರಿಣಾಮಕಾರಿತ್ವದ ಆಧಾರ. PRECISION ನಲ್ಲಿ ಹೆಚ್ಚಿನ ಹೃದಯರಕ್ತನಾಳ ಅಪಾಯದ 24,081 ಸಂಧಿವಾತ ರೋಗಿಗಳಿದ್ದರು; ಅಧ್ಯಯನವು noninferiority ಅನ್ನು ಪರೀಕ್ಷಿಸಿತು. ಹೊಸ ಉತ್ಪನ್ನದ ಮೌಲ್ಯಕ್ಕೆ ಆರಂಭದ ವೇಗ, ಬಳಕೆಯ ಸುಲಭತೆ, ಪ್ರವೇಶ ಅಥವಾ ಫಲಿತಾಂಶಗಳ ನಿರ್ದಿಷ್ಟ ಸಾಕ್ಷ್ಯ ಬೇಕು. 1974 Motrin ಮತ್ತು 1984 Advil ಅನುಮೋದನೆಗಳನ್ನು ಪ್ರಸ್ತುತ ಬೆಲೆ, ಪೇಟೆಂಟ್ ಸ್ವಾತಂತ್ರ್ಯ ಅಥವಾ ಮಾರಾಟದ ಸಾಕ್ಷ್ಯವೆಂದು ಪರಿಗಣಿಸಬಾರದು.
ಮಿತಿಗಳು: ಇದು ವೈಯಕ್ತಿಕ ಚಿಕಿತ್ಸಾ ಸಲಹೆಯಲ್ಲ. ಮೂಲ ಅಧ್ಯಯನದ ಸಂದರ್ಭ ಮತ್ತು ಸಂಪೂರ್ಣ ಉತ್ಪನ್ನ ಎಚ್ಚರಿಕೆಗಳು ಅನ್ವಯಿಸುತ್ತವೆ.
Evidence: Established within cited study scope. Sources: MECH; COCHRANE; PRECISION; REG
Marathi
Pharmacist
आयबुप्रोफेन COX-1 आणि COX-2 चे उलटू शकणारे अवरोधन करते. दाह असलेल्या ऊतींमध्ये प्रोस्टॅनॉइड निर्मिती कमी झाल्याने वेदना कमी होतात. शस्त्रक्रियेनंतरच्या वेदनांच्या अभ्यासांत 400 mg साठी NNT 2.5 होता; परिणाम म्हणजे 4–6 तासांत किमान 50% वेदनाशमन. ॲस्पिरिनचे औषधरूप आणि वेळापत्रक स्वतंत्रपणे तपासा. लेबलवरील चौकटबद्ध इशाऱ्यांत हृदयविकाराचा झटका, पक्षाघात आणि गंभीर जठरांत्रीय रक्तस्राव येतात. अतिसंवेदनशीलता, ॲस्पिरिन/NSAID मुळे आलेली ॲलर्जी, CABG शस्त्रक्रियेच्या आसपासचा वापर आणि पूर्वीची गंभीर NSAID त्वचा प्रतिक्रिया तपासणे आवश्यक आहे.
मर्यादा: ही वैयक्तिक उपचाराची सूचना नाही. मूळ अभ्यासाचा संदर्भ आणि उत्पादनाचे संपूर्ण इशारे लागू राहतात.
Evidence: Established within cited study scope. Sources: RX; MECH; COCHRANE; ASPIRIN
Clinician
आयबुप्रोफेनच्या COX-1/COX-2 अवरोधनामुळे दाहयुक्त ऊतींतील प्रोस्टॅनॉइड निर्मिती कमी होते आणि वेदना व कार्यक्षमता सुधारू शकतात. उच्च मात्रांच्या अभ्यासांत प्रमुख कोरोनरी घटनांचा RR 2.22 होता; प्रमुख रक्तवाहिनीसंबंधी घटनांच्या RR 1.44 च्या विश्वास मर्यादेत 1 येतो. हे वेगवेगळे परिणाम आहेत. मूळ हृदय, जठरांत्रीय आणि मूत्रपिंड जोखीम विचारात घ्या. गंभीर हृदयवहिन्यासंबंधी व जठरांत्रीय घटनांचे चौकटबद्ध इशारे कायम ठेवा. ॲलर्जी, CABG संदर्भ आणि पूर्वीची गंभीर NSAID त्वचा प्रतिक्रिया हे वापर टाळण्याचे संदर्भ आहेत. NICE चे ऑस्टिओआर्थ्रायटिस मार्गदर्शन योग्य परिस्थितीत स्थानिक NSAID प्रथम विचारात घेते.
मर्यादा: ही वैयक्तिक उपचाराची सूचना नाही. मूळ अभ्यासाचा संदर्भ आणि उत्पादनाचे संपूर्ण इशारे लागू राहतात.
Evidence: Established within cited study scope. Sources: RX; MECH; CNT; NICE
Nurse
आयबुप्रोफेन ऊतींतील COX-1 आणि COX-2 रोखते; प्रोस्टॅग्लँडिन निर्मिती कमी झाल्याने वेदना किंवा ताप कमी होऊ शकतो. देण्यापूर्वी लक्षणांची तीव्रता, कार्याचे उद्दिष्ट, औषधरूप आणि मागील मात्रा नोंदवा. साध्या गोळीची रक्तातील कमाल पातळी 1–2 तासांत येते; सर्वांसाठी हा पुनर्मूल्यांकनाचा निश्चित वेळ नाही. रक्तस्राव, द्रवस्थिती, लघवीचे प्रमाण आणि रक्तदाबातील बदल काळजी योजनेनुसार पाहा. गंभीर हृदयवहिन्यासंबंधी व जठरांत्रीय घटनांचे चौकटबद्ध इशारे आहेत. ॲलर्जी, CABG आणि पूर्वीच्या गंभीर NSAID त्वचा प्रतिक्रियेचा इतिहास तपासा. चिंताजनक बदल योग्य वैद्यकीय मार्गाने कळवा.
मर्यादा: ही वैयक्तिक उपचाराची सूचना नाही. मूळ अभ्यासाचा संदर्भ आणि उत्पादनाचे संपूर्ण इशारे लागू राहतात.
Evidence: Established within cited study scope. Sources: RX; OTC; MECH
Student
COX-1 आणि COX-2 अरॅकिडॉनिक आम्लापासून प्रोस्टॅनॉइड पूर्वद्रव्ये तयार होण्याच्या मार्गात कार्य करतात. आयबुप्रोफेन हे पाऊल उलटू शकणाऱ्या पद्धतीने रोखते. दाहयुक्त ऊतींमध्ये कमी प्रोस्टॅग्लँडिन संकेतांमुळे वेदनांची संवेदनशीलता कमी होते. तापाचे मार्ग आणि पोट व मूत्रपिंडांचे संरक्षण करणारे मार्ग वेगळे समजून घ्या. 1.8–2 तासांचे सीरम अर्धायुष्य औषधाचे निर्मूलन दर्शवते; ते मात्रांमधील अंतर ठरवत नाही. ॲस्पिरिनचे प्लेटलेट COX वरील अपरिवर्तनीय अॅसिटिलेशन आणि आयबुप्रोफेनचे उलटू शकणारे बंधन यांची तुलना करा. प्रयोगशाळेतील परिणाम आणि रुग्णातील लाभ एकच मोजमाप नाहीत.
मर्यादा: ही वैयक्तिक उपचाराची सूचना नाही. मूळ अभ्यासाचा संदर्भ आणि उत्पादनाचे संपूर्ण इशारे लागू राहतात.
Evidence: Established within cited study scope. Sources: RX; MECH; PHYS; ASPIRIN
Scientist
वेदनाशमनाचा अभ्यास करताना COX-1/COX-2 अवरोधन, ऊतींतील औषधाचा संपर्क आणि प्रोस्टॅनॉइड परिणाम वेगळे मोजावेत. Neupert यांच्या मानवी संपूर्ण रक्तातील चाचण्यांत S-आयबुप्रोफेनचे IC50 प्लेटलेट COX-1 साठी 2.1 μM आणि मोनोसाइट COX-2 साठी 1.6 μM होते. Evans यांच्या चार निरोगी पुरुषांच्या अभ्यासात अबद्ध S-आयबुप्रोफेनचा EC50 9.8 μg/L होता; परिणाम शरीराबाहेर मोजलेली प्लेटलेट थ्रॉम्बॉक्सेन निर्मिती होता. ही मानवी वेदनाशमनाची सार्वत्रिक मर्यादा नाही. एनॅन्टिओमर, सब्स्ट्रेट, प्रथिनांचे वातावरण आणि नमुना घेण्याची वेळ नमूद केल्याशिवाय सामर्थ्याची तुलना अपुरी राहते.
मर्यादा: ही वैयक्तिक उपचाराची सूचना नाही. मूळ अभ्यासाचा संदर्भ आणि उत्पादनाचे संपूर्ण इशारे लागू राहतात.
Evidence: Established within cited study scope. Sources: STEREO; PD; MECH
Chemist
आयबुप्रोफेन हे कायरल अरिलप्रोपिऑनिक आम्ल आहे. COX-1/COX-2 चे उलटू शकणारे अवरोधन दाहयुक्त ऊतींतील प्रोस्टॅनॉइड निर्मिती आणि वेदना कमी करते. उंदराच्या COX-2 च्या 4PH9 रचनेत S-आयबुप्रोफेन व त्याच्या कार्बॉक्सिलेटजवळील Arg120 आणि Tyr355 यांचा संदर्भ मिळतो. मेंढीच्या COX-1 ची 1EQG रचना दुसऱ्या आयसोफॉर्मची तुलना देते. मानवी पुराव्याच्या आढाव्यानुसार R अंशापैकी सुमारे 50–60% S मध्ये बदलतो. पाण्यातील विद्राव्यता 1 mg/mL पेक्षा कमी आहे. बंधन, स्टिरिओरसायनशास्त्र, औषधरूप आणि क्लिनिकल कामगिरी यांची स्वतंत्र चाचणी आवश्यक आहे.
मर्यादा: ही वैयक्तिक उपचाराची सूचना नाही. मूळ अभ्यासाचा संदर्भ आणि उत्पादनाचे संपूर्ण इशारे लागू राहतात.
Evidence: Established within cited study scope. Sources: STRUCT; STEREO; RX; MECH
Investor / Diligence Analyst
आयबुप्रोफेनचे COX-1/COX-2 अवरोधन दाहयुक्त ऊतींतील प्रोस्टॅनॉइड संकेत कमी करून स्थापित वेदनाशमन देते. शस्त्रक्रियेनंतरच्या वेदनांसाठी 400 mg वरील एकत्रित NNT 2.5 हा परिणामकारकतेचा आधार आहे. PRECISION मध्ये वाढलेल्या हृदयवहिन्यासंबंधी जोखमीचे 24,081 संधिवात रुग्ण होते; अभ्यासाने noninferiority तपासली. नवीन उत्पादनाच्या मूल्यासाठी वेदनाशमनाचा प्रारंभ, वापरण्याची सोय, उपलब्धता किंवा परिणाम यांचा उत्पादनविशिष्ट पुरावा हवा. 1974 मधील Motrin आणि 1984 मधील Advil मान्यता म्हणजे आजची किंमत, पेटंटमुक्त वापर किंवा विक्रीचा पुरावा नव्हे. नियामक मार्ग आणि निव्वळ अर्थकारण स्वतंत्रपणे तपासा.
मर्यादा: ही वैयक्तिक उपचाराची सूचना नाही. मूळ अभ्यासाचा संदर्भ आणि उत्पादनाचे संपूर्ण इशारे लागू राहतात.
Evidence: Established within cited study scope. Sources: MECH; COCHRANE; PRECISION; REG
Twelve-term glossary — five languages
| English | Spanish | Hindi | Kannada | Marathi |
|---|---|---|---|---|
| Prostaglandin | Prostaglandina | प्रोस्टाग्लैंडिन | ಪ್ರೊಸ್ಟಾಗ್ಲ್ಯಾಂಡಿನ್ | प्रोस्टॅग्लँडिन |
| COX (cyclooxygenase) | COX (ciclooxigenasa) | COX (साइक्लोऑक्सीजनेज़) | COX (ಸೈಕ್ಲೋಆಕ್ಸಿಜನೇಸ್) | COX (सायक्लोऑक्सिजनेज) |
| Enzyme | Enzima | एंज़ाइम | ಕಿಣ್ವ | विकर / एन्झाइम |
| Inflammation | Inflamación | सूजन (प्रदाह) | ಉರಿಯೂತ | दाह |
| Fever | Fiebre | बुखार | ಜ್ವರ | ताप |
| Dose | Dosis | खुराक | ಡೋಸ್ / ಔಷಧದ ಪ್ರಮಾಣ | मात्रा |
| Interval | Intervalo entre dosis | खुराकों के बीच अंतराल | ಡೋಸ್ಗಳ ನಡುವಿನ ಅಂತರ | मात्रांमधील अंतर |
| Interaction | Interacción entre medicamentos | दवाओं की परस्पर क्रिया | ಔಷಧಗಳ ಪರಸ್ಪರ ಕ್ರಿಯೆ | औषधांचा परस्परसंवाद |
| Ulcer | Úlcera | अल्सर / छाला | ಹುಣ್ಣು | व्रण / अल्सर |
| Kidney | Riñón | गुर्दा | ಮೂತ್ರಪಿಂಡ | मूत्रपिंड |
| Enantiomer | Enantiómero | एनैन्टियोमर | ಎನಾಂಟಿಯೊಮರ್ | एनॅन्टिओमर |
| Formulation | Forma farmacéutica | औषध-रूप | ಔಷಧ ರೂಪ | औषधरूप |
Translation QA checklist
- Seven distinct roles in each target language; no patient paragraph reused as a professional answer.
- Check COX isoforms, tissue and measured effect; preserve NNT endpoint, dose, units, number and trial scope.
- Check reversible versus irreversible, R fraction versus whole dose, unbound versus total concentration, noninferiority versus superiority, and dates versus current commercial facts.
- Ensure warnings and contraindications in pharmacist, clinician and nurse views remain readable with linked full label.
- Check local vocabulary and script rendering with a native health professional; English Flesch–Kincaid is not a valid test for these scripts.
- Provide bilingual review with corrections recorded; do not activate translated audio from a reviewed introduction alone.
[FOUNDER TO SUPPLY: Kannada and Marathi native-speaking health-professional reviewer names, credentials, review dates and dispositions; glossary review across all five languages.] [VERIFY: native accuracy, plain-language comprehension, fonts, screen-reader pronunciation, role routing and complete-script localization scope before multilingual release.]